Title,Analyse PDF,Authors,Category,DOI/PMID,File,Indication,Journal,Key takeaways,Relation,Reviewed,Source URL,Status,Summary,Type,Year
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease,,"Marine Berquez, Jonathan R. Gadsby, Beatrice Paola Festa, Richard Butler, Stephen P. Jackson, Valeria Berno, Alessandro Luciani, Olivier Devuyst, Jennifer L. Gallop",Nephrology,https://doi.org/10.1016/j.kint.2020.05.040,Articles%20database/10.1016j.kint.2020.05.040.pdf,"Lowe syndrome, Dent disease, Ocrl",Kidney International,"Alpelisib rebalances phosphoinositides, reduces endosomal F-actin, restores megalin and receptor-mediated endocytosis, and lowers low-molecular-weight proteinuria in an Ocrl-deficient mouse—proof-of-concept for repurposing in Lowe syndrome/Dent disease 2.",,Yes,,Done,"Alpelisib, a selective class IA PI3K (p110α) inhibitor, reduces aberrant endosomal actin in OCRL-deficient kidney cells by lowering PI(3,4,5)P3, PI(4,5)P2 and PI(3)P levels. It restores megalin at the apical membrane, improves receptor-mediated endocytosis in proximal tubule cells, and reduces low-molecular-weight proteinuria in a humanized Ocrl mouse, supporting repurposing.",Preclinical,2020
The Oculocerebrorenal Syndrome Gene Product Is a 105-kD Protein Localized to the Golgi Complex,,"Isabelle M. Olivos-Glander, Pasi A. Janne, Robert L. Nussbaum",Genetics,,Articles%20database/ajhg00036-0081.pdf,Lowe syndrom,American Journal of Human Genetics,"OCRL-1 is a 105-kD Golgi-localized protein, ubiquitously expressed and absent in Lowe patient fibroblasts; it has PIP2 5-phosphatase activity implicating disrupted Golgi membrane trafficking in Lowe syndrome.",,Yes,,Done,"The study generated antibodies to OCRL-1 and identified a single ~105 kD protein present in normal human cells and absent in patient fibroblasts lacking OCRL-1 transcript. OCRL-1 is ubiquitously expressed, localizes to the Golgi, and the mouse orthologue (106–109 kD) is similarly expressed. Findings link OCRL-1 PIP2 5-phosphatase activity to Golgi membrane trafficking, suggesting mechanisms for Lowe syndrome.",Preclinical,1995
Modeling the neuropsychiatric manifestations of Lowe syndrome using induced pluripotent stem cells: defective F-actin polymerization and WAVE-1 expression in neuronal cells,,"Jesse Barnes, Franklin Salas, Ryan Mokhtari, Hedwig Dolstra, Erika Pedrosa, Herbert M. Lachman",Neurodevelopment,10.1186/s13229-018-0227-3,Articles%20database/barnes2018.pdf,"Lowe syndrome, OCRL",Molecular Autism,"Patient-derived iPSC neurons with hypomorphic OCRL variants show decreased F-actin and abnormal WAVE-1; PI(4,5)P2 is increased in OCRL-deficient cells. An engineered OCRL null line lacked the F-actin/WAVE-1 defects, suggesting compensatory mechanisms.",,Yes,,Done,"Using iPSC-derived neural progenitors and neurons from Lowe syndrome patients and a CRISPR OCRL-null line, the study found patient hypomorphic OCRL variants cause reduced F-actin fibers and disorganized WAVE-1, with elevated PI(4,5)P2. OCRL null cells did not recapitulate the F-actin/WAVE-1 defects, suggesting compensation.",Preclinical,2018
Mouse Model for Lowe Syndrome/Dent Disease 2 Renal Tubulopathy,,"Susan P. Bothwell, Emily Chan, Isa M. Bernardini, Yien-Ming Kuo, William A. Gahl, Robert L. Nussbaum",Renal Tubulopathy,10.1681/ASN.2010050565,Articles%20database/bothwell2010.pdf,"Lowe syndrome, Dent Disease 2, INPP5B",Journal of the American Society of Nephrology,"Human INPP5B expression in Ocrl-deficient, Inpp5b-null mice produced growth retardation, low molecular-weight proteinuria and generalized aminoaciduria mirroring Lowe syndrome/Dent Disease 2; phenotype severity depended on INPP5B gene dosage.",,Yes,,Done,"Researchers generated Ocrl-deficient, Inpp5b-null mice expressing human INPP5B and observed reduced postnatal growth, low molecular-weight proteinuria, and generalized aminoaciduria resembling Lowe syndrome and Dent Disease 2. The phenotype was dose-dependent on INPP5B copy number, creating the first relevant animal model for OCRL/DD2 renal tubulopathy.",Preclinical,2011
Lowe Syndrome Protein OCRL1 Interacts with Clathrin and Regulates Protein Trafficking between Endosomes and the Trans-Golgi Network,,"Rawshan Choudhury, Aipo Diao, Fang Zhang, Evan Eisenberg, Agnes Saint-Pol, Catrin Williams, Athanasios Konstantakopoulos, John Lucocq, Ludger Johannes, Catherine Rabouille, Lois E. Greene, Martin Lowe",Cell Biology / Membrane Trafficking,10.1091/mbc.E05-02-0120,Articles%20database/choudhury2005.pdf,"Lowe syndrome, OCRL1",Molecular Biology of the Cell,"OCRL1 is present on the TGN and early endosomes, binds clathrin heavy chain terminal domain, promotes clathrin assembly, and regulates endosome-to-TGN retrograde trafficking; its loss or overexpression disrupts CI-MPR and Shiga toxin transport.",,Yes,,Done,"OCRL1 localizes to the trans-Golgi network and early endosomes and is enriched in clathrin-coated vesicles. OCRL1 binds directly to the clathrin heavy chain terminal domain and promotes clathrin assembly in vitro. Overexpression or depletion perturbs endosome–TGN trafficking (CI-MPR, STxB), implicating OCRL1 in clathrin-mediated retrograde transport and suggesting trafficking defects may contribute to Lowe syndrome.",Preclinical,2005
Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins,,"Kayalvizhi Madhivanan, Swetha Ramadesikan, Wen-Chieh Hsieh, Mariana C. Aguilar, Claudia B. Hanna, Robert L. Bacallao, R. Claudio Aguilar",Molecular genetics,10.1093/hmg/ddaa086,Articles%20database/ddaa086.pdf,Lowe syndrom,Human Molecular Genetics,OCRL1-deficient cells exhibit RhoA/MLCK-driven adhesion/spreading defects and PI3K/mTOR hyperactivation that impairs ciliogenesis. Statins correct membrane-remodeling defects; rapamycin/mTOR inhibitors restore ciliogenesis; combined treatment rescues both.,,Yes,,Done,"OCRL1-deficient (Lowe syndrome) patient cells show two independent defects: RhoGTPase (RhoA/MLCK)-dependent adhesion, spreading and fluid-phase uptake abnormalities, and PI3K/mTOR hyperactivation impairing primary ciliogenesis. Statins (rosuvastatin) mitigate membrane-remodeling defects; rapamycin and other mTOR inhibitors restore ciliogenesis. Combination treatment rescues both phenotypes, suggesting dual pathways require combinatorial therapy.",Preclinical,2020
Impaired neural development in a zebrafish model for Lowe syndrome,,"Irene Barinaga-Rementeria Ramirez, Grzegorz Pietka, David R. Jones, Nullin Divecha, A. Alia, Scott C. Baraban, Adam F. L. Hurlstone, Martin Lowe",Neurology/Genetics,10.1093/hmg/ddr608,Articles%20database/ddr608.pdf,Lowe syndrom,Human Molecular Genetics,"OCRL1 deficiency elevates PtdIns(4,5)P2, impairs Akt signalling, increases neural apoptosis, reduces proliferation, causes seizure susceptibility and periventricular cystic lesions; OCRL1 catalytic activity and clathrin binding are essential.",,Yes,,Done,"Zebrafish deficient for OCRL1 model Lowe syndrome neurological defects: elevated PtdIns(4,5)P2, increased susceptibility to heat-induced seizures, and periventricular cystic brain lesions. OCRL1 loss reduces Akt signalling, increases apoptosis and decreases proliferation in neural tissue. Rescue requires OCRL1 catalytic activity and clathrin binding.",Preclinical,2012
Autophagosome–lysosome fusion triggers a lysosomal response mediated by TLR9 and controlled by OCRL,,"Maria Giovanna De Leo, Leopoldo Staiano, Mariella Vicinanza, Alessandro Luciani, Annamaria Carissimo, Margherita Mutarelli, Antonella Di Campli, Elena Polishchuk, Giuseppe Di Tullio, Valentina Morra, Elena Levtchenko, Francesca Oltrabella, Tobias Starborg, Michele Santoro, Diego di Bernardo, Olivier Devuyst, Martin Lowe, Diego L. Medina, Andrea Ballabio, Maria Antonietta De Matteis",Cell biology,10.1038/ncb3386,Articles%20database/deleo2016.pdf,Lowe syndrome,Nature Cell Biology,"mtDNA delivered by autophagosomes activates lysosomal TLR9, driving local PtdIns(4,5)P2 production and recruitment of AP2/clathrin and OCRL. OCRL restricts PtdIns(4,5)P2 to maintain MCOLN1 activity; OCRL loss inhibits MCOLN1, blocking fusion and accumulating autophagosomes.",,Yes,,Done,"The study identifies a lysosomal response to autophagosomal cargo: mitochondrial DNA delivered to lysosomes activates TLR9, inducing local PtdIns(4,5)P2 production and recruitment of AP2/clathrin and OCRL. OCRL limits lysosomal PtdIns(4,5)P2 to preserve MCOLN1 calcium-channel activity and autophagosome–lysosome fusion. OCRL loss causes PtdIns(4,5)P2 accumulation, MCOLN1 inhibition and autophagosome accumulation in cells and Lowe syndrome kidneys; MCOLN1 agonists restore autophagic flux, suggesting a potential therapeutic approach.",Preclinical,2016
A Role of the Lowe Syndrome Protein OCRL in Early Steps of the Endocytic Pathway,,"Kai S. Erdmann, Yuxin Mao, Heather J. McCrea, Roberto Zoncu, Sangyoon Lee, Summer Paradise, Jan Modregger, Daniel Biemesderfer, Derek Toomre, Pietro De Camilli",Cell Biology (Endocytosis / Membrane trafficking),10.1016/j.devcel.2007.08.004,Articles%20database/erdmann2007.pdf,Lowe syndrome,Developmental Cell,"OCRL visits endocytic clathrin-coated pits and binds APPL1 on early endosomes via ASH-RhoGAP-like domains; Lowe syndrome mutations abolish this interaction. Structure reveals clathrin box and domain arrangement, linking OCRL to receptor trafficking in kidney and brain.",,Yes,,Done,"OCRL localizes to early endocytic compartments, including a subset of clathrin-coated pits, and binds the Rab5 effector APPL1 on peripheral early endosomes via its ASH–RhoGAP-like domains. Disease-linked mutations disrupt APPL1 binding. Crystal structure shows domain arrangement and a clathrin box, supporting OCRL’s role in early endocytic trafficking relevant to Lowe syndrome.",Preclinical,2007
The Lowe syndrome protein OCRL1 is involved in primary cilia assembly,,"V Hernandez, BG Coon, K Madhivanan, D Mukherjee, CB Hanna, I Barinaga-Rementeria Ramirez, M Lowe, PL Beales, RC Aguilar",Ciliopathy,10.1186/2046-2530-1-S1-P87,Articles%20database/hernandez2012.pdf,Lowe syndrom,Cilia,"OCRL1 deficiency impairs primary cilia assembly in patient and knock-down cells (rescuable by WT OCRL1); zebrafish show cilia and developmental defects. OCRL1 mediates ciliary protein trafficking via Rab8 and IPIP27/Ses, linking Lowe syndrome to ciliopathies.",,Yes,,Done,"This conference poster reports that OCRL1 is required for primary cilia assembly. Patient cells and OCRL1 knock-down cell lines show cilia assembly defects that are rescued by reintroduction of WT OCRL1. A zebrafish Lowe syndrome model exhibits cilia and developmental defects. OCRL1 functions in ciliary protein trafficking via Rab8 and IPIP27/Ses, linking Lowe syndrome to ciliopathies.",Preclinical,2012
Kidney-differentiated cells derived from Lowe Syndrome patient’s iPSCs show ciliogenesis defects and Six2 retention at the Golgi complex,,"Wen-Chieh Hsieh, Swetha Ramadesikan, Donna Fekete, Ruben Claudio Aguilar",Nephrology,10.1371/journal.pone.0192635,Articles%20database/hsieh2018.pdf,Lowe Syndrome,PLOS ONE,"LS iPSC-derived kidney cells exhibit reduced ciliogenesis and increased Six2 retention at the Golgi with decreased nuclear localization, leading to overrepresentation of ductal (Ck8+) cells; OCRL1 KO in HK2 confirms phenotypes and LiCl reduces Golgi retention.",,Yes,,Done,"iPSCs were generated from Lowe syndrome patient fibroblasts and differentiated into kidney-lineage cells. These cells showed impaired primary cilia assembly and abnormal retention of the transcription factor Six2 at the Golgi with reduced nuclear Six2, shifting lineage balance toward ductal cells. OCRL1 knockout HK2 cells recapitulated these defects; LiCl partially reversed Six2 Golgi retention.",Preclinical,2018
Transcriptome analysis of neural progenitor cells derived from Lowe syndrome induced pluripotent stem cells: identification of candidate genes for the neurodevelopmental and eye manifestations,,"Hequn Liu, Jesse Barnes, Erika Pedrosa, Nathaniel S. Herman, Franklin Salas, Ping Wang, Deyou Zheng, Herbert M. Lachman",Neurology,10.1186/s11689-020-09317-2,Articles%20database/liu_et_al_2020.pdf,Lowe syndrom,Journal of Neurodevelopmental Disorders,"RNA-seq of iPSC-derived NPCs from 3 Lowe syndrome patients vs siblings found 319 nominal DEGs (16 padj<0.1, nine padj<0.05). Notable genes: EFEMP1, MEIS2, SPON1, DPP10. GSEA: telencephalon/cortex development. OCRL knockdown increased EFEMP1 and MEIS2, linking OCRL loss to neurodevelopmental and eye defects.",,Yes,,Done,"RNA-seq of iPSC-derived neural progenitor cells from three Lowe syndrome patients and their unaffected brothers identified 319 nominal DEGs (16 at padj<0.1, nine at padj<0.05). DEGs include EFEMP1, MEIS2, SPON1 and DPP10, with enrichment for telencephalon/cortex development and overlap with ASD and eye-disease genes. OCRL knockdown increased EFEMP1 and MEIS2, linking OCRL loss to neurodevelopmental and ocular manifestations.",Preclinical,2020
Long-term kidney function of Lowe syndrome: a nationwide study of paediatric and adult patients,,"Taro Ando, Kenichiro Miura, Tomoo Yabuuchi, Yoko Shirai, Kiyonobu Ishizuka, Shoichiro Kanda, Yutaka Harita, Kyoko Hirasawa, Riku Hamada, Kenji Ishikura, Eisuke Inoue, Motoshi Hattori",Nephrology,10.1093/ndt/gfae080,Articles%20database/Long-term_kidney_function_of_Lowe_syndrome-.pdf,Lowe syndrom,Nephrol Dial Transplant,eGFR declines steeply after age 10 in Lowe syndrome; 84% had CKD G4–5 after 20 years and many progress to ESKD by their 30s. Age was the only significant correlate of eGFR; nephrocalcinosis and hypercalciuria were not associated with deterioration.,,Yes,,Done,"In a nationwide retrospective cohort of 54 males with Lowe syndrome, eGFR declined steeply after age 10. By adulthood 84% had CKD stages G4–5 and 67% of those ≥30 years reached ESKD. Age was the only factor significantly associated with eGFR; nephrocalcinosis and hypercalciuria showed no significant impact.",Retrospective multicentre cohort study,2024
A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism,,"Yuxin Mao, Daniel M Balkin, Roberto Zoncu, Kai S Erdmann, Livia Tomasini, Fenghua Hu, Moonsoo M Jin, Michael E Hodsdon, Pietro De Camilli",Membranes & transport,10.1038/emboj.2009.155,Articles%20database/mao2009.pdf,Lowe syndrom,The EMBO Journal,"OCRL and INPP5B share an N-terminal PH domain; OCRL uniquely contains a clathrin-box within this PH loop that binds clathrin. Mutating this motif lowers OCRL recruitment to coated pits and disrupts clathrin-mediated endocytosis, suggesting OCRL bridges PI metabolism to clathrin trafficking.",,Yes,,Done,"The study shows the previously uncharacterized N-terminal regions of OCRL and INPP5B contain PH domains. OCRL's PH domain harbors an unconventional clathrin-box motif that binds clathrin heavy chain, validated by pull-downs, SPR and NMR. Mutations reduce OCRL recruitment to clathrin-coated pits and impair clathrin-mediated endocytosis, linking OCRL to phosphoinositide metabolism and clathrin-dependent trafficking.",Preclinical,2009
The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin,,"Alexander Ungewickell, Michael E. Ward, Ernst Ungewickell, Philip W. Majerus",Cell Biology / Intracellular trafficking,10.1073/pnas.0405664101,Articles%20database/ungewickell2004.pdf,Lowe syndrom,Proceedings of the National Academy of Sciences (PNAS),"Ocrl localizes to Golgi and clathrin-positive endosomes containing Tf and M6PR, binds clathrin TD and AP-2 via LIDLE and FxDxF motifs, copurifies with CCVs, and likely regulates endosomal receptor trafficking and M6PR sorting.",,Yes,,Done,"Ocrl localizes to Golgi and endosomal membranes that contain clathrin, transferrin, CI-/CD-M6PR and EEA1. Ocrl binds the clathrin terminal domain and the AP-2 appendage via conserved motifs, copurifies with clathrin-coated vesicles, and likely functions in endosomal receptor trafficking and M6PR sorting, implicating a role in Lowe syndrome pathophysiology.",Preclinical,2004
Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis,,"Jennifer A. Hollywood, Aneta Przepiorski, Randall F. D’Souza, Sreevalsan Sreebhavan, Ernst J. Wolvetang, Patrick T. Harrison, Alan J. Davidson, Teresa M. Holm",Nephrology,https://doi.org/10.1681/ASN.2019070712,Articles%20database/Dr.Davidson-Holm-Hollywood-JASN-Use-of-Induced-Pluripotent-Stem-Cells-et-al.2020-March.pdf,Cystinose,Journal of the American Society of Nephrology (JASN),"In human iPSC and kidney organoid cystinosis models, cysteamine depletes cystine but fails to restore basal autophagy or reduce apoptosis. Everolimus (mTOR inhibition) activates autophagy, reduces enlarged lysosomes and apoptosis. Combined treatment corrects all phenotypes, suggesting combo therapy potential.",,Yes,,Done,"Human iPSC and kidney organoid models of cystinosis were generated showing cystine accumulation, enlarged lysosomes, increased apoptosis, and defective basal autophagy. Cysteamine lowered cystine but did not restore autophagy/apoptosis. Everolimus activated autophagy and reduced lysosomal enlargement and apoptosis. Combined cysteamine+everolimus rescued all observed phenotypes, suggesting therapeutic potential.",Preclinical,2020
Protocol for Large-Scale Production of Kidney Organoids from Human Pluripotent Stem Cells,,"Veronika Sander, Aneta Przepiorski, Amanda E. Crunk, Neil A. Hukriede, Teresa M. Holm, Alan J. Davidson",Regenerative Medicine / Nephrology (Organoid methods),10.1016/j.xpro.2020.100150,Articles%20database/sander_et_al._(2023)_protocol.pdf,,STAR Protocols,"Two-step suspension protocol enabling rapid, cost-effective bulk production of hPSC-derived kidney organoids containing major renal cell types. Organoids correspond to fetal human kidney, optimal for assays day 12–20, limited for modeling adult kidney function.",,Yes,,Done,"Describes a simple two-step suspension culture protocol to differentiate human pluripotent stem cells into kidney organoids. The method is rapid, low-cost and scalable for large assays (e.g., drug screening). Organoids resemble fetal human kidney and are optimal between day 12–20; limited for adult kidney modeling.",Protocol (Preclinical),2020
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids,,"Taisuke Furusho, Kei Adachi, Mia Galbraith-Liss, Anusha Sairavi, Ranjan Das, Hiroyuki Nakai",Gene therapy,10.1101/2023.07.28.548760,Articles%20database/Enhancing_gene_transfer_to_renal_tubules_and_podocytes_by_context-_dependent_selection_of_AAV_capsids.pdf,CKD (kronisk nyresygdom),bioRxiv,"AAV Barcode-Seq of 47 capsids identified six capsids (AAV-KP1, KP2, KP3, DJ, 2G9, 2.7m8) that enhance renal transduction after local renal vein or pelvis delivery. AAV-KP1 yields proximal tubule transduction with reduced liver spillover; AAV9 transduces podocytes and tubules efficiently in CKD due to altered pharmacokinetics.",,Yes,,Done,"Using AAV Barcode-Seq to compare 47 capsids in mice, the authors identified six capsids (AAV-KP1, KP2, KP3, DJ, 2G9, 2.7m8) that markedly improve renal transduction when delivered locally (renal vein or pelvis). AAV-KP1 via local delivery efficiently transduces proximal tubules while reducing liver off-targeting. In a CKD mouse model, systemic AAV9—but not KP1—efficiently transduces proximal tubules and podocytes, linked to distinct pharmacokinetics. The study emphasizes context-dependent capsid and route selection for renal gene therapy.",Preclinical,2023
Kidney organoids to model inherited kidney diseases,,,Nephrology,,Articles%20database/Sebastian-CureLowe_preliminary_data.pdf,Arvelige nyresygdomme,,"Scalable disease-specific kidney organoids (OCRL, GLA, CTNS, TSC2, FLCN); OCRL-KO shows impaired proximal tubule endocytosis, megalin trafficking, autophagy and lysosome enlargement; 4/11 AAV serotypes transduce proximal tubules; AAV-OCRL gene replacement shows PoC.",,Yes,,Done,"Developed scalable generation of human kidney organoids from disease-modeled iPSCs that recapitulate nephron segment markers. Multiple KO disease models (OCRL, GLA, CTNS, TSC2, FLCN) were produced. OCRL-KO organoids show proximal tubule endocytic and autophagy defects; AAV-mediated OCRL replacement shows proof-of-concept rescue.",Preclinical,
Advancing Lowe Syndrome Treatment with AAV-OCRL Gene Therapy,,"Qing Wang, Siyu Chen, Chien-Hui Lo, Zhiquan Liu, Tia J. Kowal, Biao Wang, Yang Sun","Gene therapy, Ophthalmology",,Articles%20database/YangSun_Lowe_AAV_Fibroblast_Mice_Study_Unpublished_Manuscript_Draft.pdf,Lowe syndrom,,"AAV-OCRL gene augmentation reduces PI(4,5)P2, restores ciliogenesis and actin organization in cells, and lowers IOP while improving outflow in Lowe syndrome mice, though retinal thickness and ERG responses were not improved.",,Yes,,Done,"AAV-mediated OCRL (AAV2-3M-HA-hOCRL) restored OCRL function in cellular models by reducing PI(4,5)P2, rescuing cilia length and correcting actin/α-actinin abnormalities. In a Lowe syndrome mouse model it lowered intraocular pressure and improved aqueous outflow; retinal thickness and ERG were unchanged.",Preclinical,
PreIND Briefing Book: Melpida (Written responses by 14 May 2021),,"Terry Pirovolakis, Lauren Black, Julie Douville, Stefania Cinquino, Steven Gray, Xin Chen, Carsten Bonnemann, Dimah Saade, James J. Dowling, Juan Bonifacino, Raffaella De Pace, Darius Ebrahimi-Fakhari, Mustafa Sahin, Diane Balderson",Neurology (Gene therapy development),,Articles%20database/Pre-IND_Full_Submission-compress.pdf,SPG50,,Melpida (scAAV9-hAP4M1opt) proposed as one-time intrathecal gene therapy for SPG50. Patient fibroblasts and mouse studies show restored ATG9A trafficking and sustained brain expression; no severe toxicity observed in mouse studies; 12-week GLP rat tox ongoing to support IND planned in 2H2021.,,Yes,,Done,"Sponsor CureSPG50 proposes Melpida: a single intrathecal scAAV9 delivering codon-optimized human AP4M1 to treat pediatric SPG50. Preclinical ex vivo and in vivo data show target engagement, dose-dependent brain expression and phenotypic rescue in models; ongoing GLP rat toxicology to support a 2H2021 IND.",PreIND meeting briefing (Regulatory),2021
Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman Primates,,"Kathrin Meyer, Laura Ferraiuolo, Leah Schmelzer, Lyndsey Braun, Vicki McGovern, Shibi Likhite, Olivia Michels, Alessandra Govoni, Julie Fitzgerald, Pablo Morales, Kevin D Foust, Jerry R Mendell, Arthur HM Burghes, Brian K Kaspar",Gene therapy,10.1038/mt.2014.210,Articles%20database/Improving_Single_Injection_CSF_Delivery_of_AAV9-mediated_Gene_Therapy_for_SMA_A_Dose-response_Study_in_Mice_and_Nonhuman_Primates.pdf,SMA,Molecular Therapy,Single CSF delivery of scAAV9-SMN achieves widespread spinal cord and brain transduction at lower doses than IV; 1.8e13 vg/kg ICV was minimally effective in mice. Trendelenburg positioning improves distribution in nonhuman primates and peripheral exposure is reduced.,,Yes,,Done,Single CSF injection of scAAV9-SMN in mice and nonhuman primates produced widespread CNS transduction at ~10x lower doses than IV. In mice the minimal effective ICV dose was 1.8e13 vg/kg (median survival 165 days); higher doses further extended survival. Trendelenburg positioning improved cranial/spinal spread. CSF delivery reduced peripheral transduction versus systemic dosing.,Preclinical,2015
A large animal model of Spinal Muscular Atrophy and correction of phenotype,,"Sandra I. Duque, W. David Arnold, Philipp Odermatt, Xiaohui Li, Paul N. Porensky, Leah Schmelzer, Kathrin Meyer, Stephen J. Kolb, Daniel Schümperli, Brian K. Kaspar, Arthur H. M. Burghes",Neurology,10.1002/ana.24332,Articles%20database/A_large_animal_model_of_Spinal_Muscular_Atrophy_and_correction_of_phenotype.pdf,SMA,Annals of Neurology,"SMN knockdown in postnatal motoneurons causes SMA-like weakness, denervation, reduced CMAP/MUNE and motoneuron/axon loss. scAAV9-SMN prevents disease if given pre-symptomatically and partially reverses phenotype and electrophysiological biomarkers when given after symptom onset.",,Yes,,Done,"Postnatal intrathecal scAAV9-delivered shRNA knockdown of pig SMN produced a large-animal (pig) SMA phenotype with motor neuron/axon loss, reduced CMAP/MUNE and fibrillations. Delivery of scAAV9-SMN prevented disease when given pre-symptomatically and substantially improved phenotype, electrophysiology and pathology when given after symptom onset.",Preclinical,2015
Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy,,"Nicole Armbruster, Annalisa Lattanzi, Matthieu Jeavons, Laetitia Van Wittenberghe, Bernard Gjata, Thibaut Marais, Samia Martin, Alban Vignaud, Thomas Voit, Fulvio Mavilio, Martine Barkats, Ana Buj-Bello",Gene therapy,10.1038/mtm.2016.60,Articles%20database/Efficacy_and_biodistribution_analysis_of_intracerebroventricular_administration_of_an_optimised_scAAV9-SMN1_vector_in_a_mourse_model_of_spinal_muscular_atrophy.pdf,SMA,Molecular Therapy — Methods & Clinical Development,"ICV scAAV9-coSMN1 in SMNΔ7 mice gives dose-dependent long-term rescue (median survival up to 346 days, max 406), achieves CNS and peripheral SMN expression; IV coadministration increases peripheral load but does not improve survival, supporting CSF delivery.",,Yes,,Done,"Intracerebroventricular (ICV) delivery of scAAV9-coSMN1 in neonatal SMNΔ7 mice produced a dose-dependent, long-term rescue of SMA with optimal median survival of 346 days (max 406). Robust CNS transduction and peripheral SMN expression occurred; adding IV did not further improve survival. Supports CSF AAV delivery for SMA gene therapy.",Preclinical,2016
Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies,,"Xin Chen, Thomas Dong, Yuhui Hu, Raffaella De Pace, Rafael Mattera, Kathrin Eberhardt, Marvin Ziegler, Terry Pirovolakis, Mustafa Sahin, Juan S. Bonifacino, Darius Ebrahimi-Fakhari, Steven J. Gray",Neurology,10.1172/JCI164575,Articles%20database/Intrathecal_AAV9_AP4M1_gene_therapy_for_hereditary_spastic_paraplegia_50_shows_safety_and_efficacy_in_preclinical_studies.pdf,SPG50,The Journal of Clinical Investigation,"AAV9/AP4M1 via intrathecal delivery rescues cellular phenotypes, partially normalizes behavior in Ap4m1-KO mice in an age- and dose-dependent manner, and exhibits acceptable preclinical safety (minimal-to-mild DRG findings) supporting a phase I trial.",,Yes,,Done,"Intrathecal AAV9/AP4M1 restored AP4M1 expression and ATG9A trafficking in patient fibroblasts, produced dose- and age-dependent behavioral improvement in Ap4m1-KO mice, and showed an acceptable safety profile in mice, rats, and NHPs up to a human-equivalent dose of ~1×10^15 vg, supporting clinical translation.",Preclinical,2023
Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice,,"Elisa Dominguez, Thibaut Marais, Nicolas Chatauret, Sofia Benkhelifa-Ziyyat, Sandra Duque, Philippe Ravassard, Romain Carcenac, Stéphanie Astord, Aurélie Pereira de Moura, Thomas Voit, Martine Barkats",Gene therapy,10.1093/hmg/ddq514,Articles%20database/Intravenous_scAAV9_delivery_of_a_codon-optimized_SMN1_sequence_rescues_SMA_mice.pdf,SMA,Human Molecular Genetics,"Single neonatal IV delivery of scAAV9-SMNopti fully rescued severe SMA mice: 100% treated survival, median lifespan 199 days (some >340), restored motor function, prevented MN death and corrected weight loss—supports systemic scAAV9-SMNopti as a promising therapy.",,Yes,,Done,"In neonatal SMA mice, a single intravenous injection of scAAV9 carrying a codon-optimized SMN1 (SMNopti) produced robust SMN expression in spinal cord and muscle, rescued motor neuron survival, normalized weight and motor function, and extended median survival from ~13 days to 199 days (some >340 days).",Preclinical,2011
Lessons Learned from the Clinical Development and Market Authorization of Glybera,,"Laura M. Bryant, Devin M. Christopher, April R. Giles, Christian Hinderer, Jesse L. Rodriguez, Jenessa B. Smith, Elizabeth A. Traxler, Josh Tycko, Adam P. Wojno, James M. Wilson",Gene therapy / Clinical development,10.1089/humc.2013.087,Articles%20database/Lessons_Learned_from_the_Clinical_Development_anf_Market_Authorization_of_Glybera.pdf,LPL deficiency,Human Gene Therapy Clinical Development,Glybera received EU approval (Nov 2012) for LPL deficiency despite transient TG lowering; postprandial chylomicron clearance showed functional LPL expression. Approval limited to patients with recurrent pancreatitis and accompanied by strict postmarketing requirements.,,Yes,,Done,"This review chronicles preclinical and clinical development of Glybera (alipogene tiparvovec), highlighting transient triglyceride reductions, sustained improvements in postprandial chylomicron clearance, immune and manufacturing challenges, and the EMA's conditional approval for a restricted LPLD patient group with required postmarketing studies.",Review,2013
Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease,,"Jolanda M.P. Liefhebber, Giso Brasser, Elisabeth A. Spronck, Roelof Ottenhoff, Lieke Paerels, Maria J. Ferraz, Lukas K. Schwarz, Nikoleta Efthymiopoulou, Chi-Lin Kuo, Paula S. Montenegro-Miranda, Melvin M. Evers, Johannes M.F.G. Aerts, Ying Poi Liu",Gene therapy,10.1016/j.omtm.2024.101375,Articles%20database/Preclinical_efficacy_and_safety_of_adeno-associated_virus_5_alpha-galactosidase_A_gene_therapy_for_Fabry_disease.pdf,,Molecular Therapy: Methods & Clinical Development,"AAV5-GLA with a novel liver-specific promoter is safe in mice and NHPs, drives durable hepatic GLA expression, yields plasma enzyme activity, reduces Gb3/lyso-Gb3 in target organs, and improves nociception—supporting progression to clinical trials.",,Yes,,Done,"Single-dose intravenous AAV5-GLA using a novel liver-restricted promoter produced robust, durable hepatic GLA expression in GLA-knockout mice and cynomolgus macaques. Dose-dependent plasma enzyme activity led to cross-correction, reduced Gb3/lyso-Gb3 in heart and kidney, improved nociception, and showed a favorable preclinical safety profile, supporting clinical trials.",Preclinical,2024
"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease",,"Jey M. Jeyakumar, Azadeh Kia, Lawrence C. S. Tam, Jenny McIntosh, Justyna Spiewak, Kevin Mills, Wendy Heywood, Elisa Chisari, Noemi Castaldo, Daniël Verhoef, Paniz Hosseini, Petya Kalcheva, Clement Cocita, Carlos J. Miranda, Miriam Canavese, Jaminder Khinder, Cecilia Rosales, Derralynn Hughes, Rose Sheridan, Romuald Corbau, Amit Nathwani",Gene therapy,10.1038/s41434-022-00381-y,Articles%20database/Preclinical_evaluation_of_FLT190_a_liver-directed_AAV_Fabry_disease.pdf,,Gene Therapy,"Single IV dose of FLT190 gave rapid, dose-dependent, durable plasma α‑Gal A increases in mice and NHPs; in Fabry mice it cleared Gb3/lyso‑Gb3 from plasma, urine, kidney and heart, reduced storage inclusion bodies, and showed no FLT190-related toxicities in NHPs.",,Yes,,Done,"FLT190, a liver-directed AAVS3-FRE1-GLAco gene therapy, produced rapid, dose-dependent and durable increases in plasma α‑Gal A in mice and non-human primates. In Fabry mice FLT190 cleared Gb3 and lyso‑Gb3 from plasma, urine, kidney and heart, reduced storage inclusions, and showed no FLT190-related toxicities in NHPs, supporting clinical evaluation.",Preclinical,2023
Preclinical pharmacology and safety studies to support an AAV9 NGLY1 gene therapy clinical trial for the treatment of NGLY1 deficiency,,"Lei Zhu, Jennifer W. Cook, Alicia Newton, Selina S. Dwight, Brendan Beahm, Matt Wilsey, William F. Mueller, Becky Schweighardt",Gene therapy / Neurology,https://doi.org/10.1016/j.omtm.2025.101524,Articles%20database/Preclinical_pharmacology_and_safety_studies_to_support_and_AAV9_NGLY1_gene_therapy_clinical_trial_for_the_treatment_of_NGLY1_deficiency.pdf,,Molecular Therapy: Methods & Clinical Development,"i.c.v. GS-100 (AAV9) produced dose-dependent CNS biodistribution and hNGLY1 expression, reduced CSF/brain GNA that correlated with motor improvements; safety acceptable at proposed 4e14 vg/individual; supported IND and initiation of phase 1/2/3 trial (NCT06199531).",,Yes,,Done,"GS-100, an AAV9-based NGLY1 gene replacement delivered i.c.v., showed dose-dependent CNS biodistribution and hNGLY1 expression in Ngly1-/- rats and NHPs, reduced the GNA biomarker in CSF and CNS, improved/maintained motor function, and ameliorated DRG pathology. GLP toxicology indicated acceptable safety near the proposed clinical starting dose (4e14 vg/individual), supporting IND approval and initiation of a phase 1/2/3 trial.",Preclinical,2025
Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy,,"Wenjing Luo, Lu Guo, Liang Lu, Nan Huang, Yezheng Tao, Yufei Zhang, Yanrong Cao, Shin-Shay Tian, Xiaoping Zhao, Xi Zhu",Gene therapy,10.1016/j.omtm.2025.101460,Articles%20database/Preclinical_studies_of_an_AAV8-CYP4V2_gene_therapy_VGR-R01_for_the_treatment_of_Bietti_crystalline_dystrophy.pdf,,Molecular Therapy: Methods & Clinical Development,"VGR-R01 drives dose-dependent CYP4V2 expression, restores hydroxylase activity, reduces RPE lipid droplets, improves ERG in Cyp4v3–/– mice, shows ocular-restricted biodistribution, and is well tolerated in rabbits and NHPs; supports phase 1/2 trial (NCT05694598).",,Yes,,Done,"VGR-R01, an AAV8-based CYP4V2 gene therapy, produced dose-dependent CYP4V2 expression, restored fatty acid hydroxylase activity, and reduced lipid droplet accumulation in RPE cells in vitro. In Cyp4v3–/– mice it improved ERG amplitudes. Biodistribution was largely ocular and the vector was well tolerated in rabbits and NHPs, supporting clinical translation (NCT05694598).",Preclinical,2025
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy,,"Rachael A. Potter, Danielle A. Griffin, Kristin N. Heller, Ellyn L. Peterson, Emma K. Clark, Jerry R. Mendell, Louise R. Rodino-Klapac",Gene therapy,10.1089/hum.2019.255,Articles%20database/potter-et-al-2021-dose-escalation-study-of-systemically-delivered-raavrh74-mhck7-micro-dystrophin-in-the-mdx-mouse.pdf,,Human Gene Therapy,"Systemic rAAVrh74.MHCK7.micro-dystrophin yielded dose-dependent muscle and heart expression, reduced fibrosis, normalized fiber size, restored diaphragm and TA force to WT levels at higher doses, lowered CK, durable for 6 months, and showed no vector toxicity.",,Yes,,Done,"Systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in mdx mice produced robust skeletal and cardiac transgene expression in a dose-dependent manner, improved histology (reduced fibrosis, normalized fiber size, reduced central nucleation), restored muscle force to near WT at intermediate/high doses, lowered CK, showed no vector-associated toxicity, and durability at 6 months, supporting Phase I/II trials.",Preclinical,2021
Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy,,"Jerry R. Mendell, Perry B. Shieh, Craig M. McDonald, Zarife Sahenk, Kelly J. Lehman, Linda P. Lowes, Natalie F. Reash, Megan A. Iammarino, Lindsay N. Alfano, Brenna Sabo, Jeremy D. Woods, Christy L. Skura, Howard C. Mao, Loretta A. Staudt, Danielle A. Griffin, Sarah Lewis, Shufang Wang, Rachael A. Potter, Teji Singh, Louise R. Rodino-Klapac",Neurology (Gene therapy),10.3389/fcell.2023.1167762,Articles%20database/fcell-11-1167762.pdf,,Frontiers in Cell and Developmental Biology,"SRP-9001 produced robust dystrophin expression in all treated patients and overall stabilization of NSAA up to 2 years. Primary NSAA endpoint not significant overall (baseline imbalance); 4–5y subgroup and Part 2 vs external control showed significant benefit. Common TRAEs: vomiting, decreased appetite, nausea.",,Yes,,Done,"In this Phase 2 randomized, double-blind crossover trial, delandistrogene moxeparvovec (SRP-9001) produced robust dystrophin expression in all treated children with DMD and stabilized motor function (NSAA) up to 2 years. Overall NSAA at 48 weeks was not significant due to baseline imbalance; subgroup and Part 2 vs external controls showed benefit. Safety was manageable.",Clinical trial (Phase 2),2023
"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial",,"John W Day, Richard S Finkel, Claudia A Chiriboga, Anne M Connolly, Thomas O Crawford, Basil T Darras, Susan T Iannaccone, Nancy L Kuntz, Loren D M Peña, Perry B Shieh, Edward C Smith, Jennifer M Kwon, Craig M Zaidman, Meredith Schultz, Douglas E Feltner, Sitra Tauscher-Wisniewski, Haojun Ouyang, Deepa H Chand, Douglas M Sproule, Thomas A Macek, Jerry R Mendell",Neurology,,Articles%20database/PIIS1474442221000016.pdf,,Lancet Neurology,"Single-dose onasemnogene abeparvovec in 22 symptomatic infants with SMA type 1 (2 SMN2 copies) led to 59% achieving independent sitting at 18 months (vs 0/23 historical) and 91% survival free of permanent ventilation at 14 months (vs 26%); safety manageable (transient LFT rises, pyrexia).",,Yes,,Done,"Phase 3 open-label STR1VE trial: single intravenous dose of onasemnogene abeparvovec in 22 symptomatic infants with SMA (2 SMN2 copies) improved outcomes vs historical controls — 59% achieved independent sitting at 18 months (vs 0/23) and 91% survived free from permanent ventilation at 14 months (vs 26%). Adverse events were common but manageable, mainly transient liver enzyme elevations and fever; overall favorable benefit–risk.",Clinical trial (Phase 3),2021
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy,,"John W. Day, Jerry R. Mendell, Eugenio Mercuri, Richard S. Finkel, Kevin A. Strauss, Aaron Kleyn, Sitra Tauscher‑Wisniewski, Francis Fonyuy Tukov, Sandra P. Reyna, Deepa H. Chand",Drug Safety / Pharmacovigilance,10.1007/s40264-021-01107-6,Articles%20database/s40264-021-01107-6.pdf,,Drug Safety,"From preclinical, clinical (n=102) and postmarketing (665 cases): hepatotoxicity resolved with prednisolone, transient thrombocytopenia, rare TMA requiring intervention, potential cardiac AEs, DRG inflammation in NHPs. Risks manageable with monitoring.",,Yes,,Done,"Integrated safety assessment of intravenous onasemnogene abeparvovec using preclinical studies, seven clinical trials (102 patients) and postmarketing reports (665 cases). Key risks: hepatotoxicity (responsive to prednisolone), transient thrombocytopenia, rare thrombotic microangiopathy, cardiac AEs, and dorsal root ganglia findings in NHPs. Risks can be anticipated, monitored, and managed.",Original research (clinical trials and postmarketing safety study),2021
Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study,,"Hugh J. McMillan, Giovanni Baranello, Michelle A. Farrar, Craig M. Zaidman, Teresa Moreno, Liesbeth De Waele, Yuh-Jyh Jong, Vincent Laugel, Susana Quijano-Roy, Eugenio Mercuri, Yin-Hsiu Chien, Volker Straub, Basil T. Darras, Julia Seibert, Roberto Bernardo Escudero, Iulian Alecu, Frank Freischlager, Francesco Muntoni",Neurology,10.1212/WNL.0000000000210268,Articles%20database/WNL-2024-104530DN.pdf,,Neurology,"In 24 children (8.5–21 kg) treated with IV onasemnogene abeparvovec, 83% had asymptomatic hepatotoxicity (transaminase elevations), 71% had transient thrombocytopenia; no Hy's law or deaths. Heavier patients needed prolonged corticosteroids. Most maintained or improved motor function by week 52.",,Yes,,Done,"Phase 3b SMART evaluated IV onasemnogene abeparvovec in symptomatic pediatric SMA patients weighing 8.5–21 kg. Safety was similar across weight groups but featured frequent asymptomatic transaminase elevations and transient thrombocytopenia; no Hy's law cases or deaths. Heavier cohorts required longer corticosteroids. Most participants maintained or improved motor function, suggesting clinical benefit.",Clinical trial (Phase 3b open-label single-arm),2025
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B,,"Amit C. Nathwani, Edward G.D. Tuddenham, Savita Rangarajan, Cecilia Rosales, Jenny McIntosh, David C. Linch, Pratima Chowdary, Anne Riddell, Arnulfo Jaquilmac Pie, Chris Harrington, James O’Beirne, Keith Smith, John Pasi, Bertil Glader, Pradip Rustagi, Catherine Y.C. Ng, Mark A. Kay, Junfang Zhou, Yunyu Spence, Christopher L. Morton, James Allay, John Coleman, Susan Sleep, John M. Cunningham, Deokumar Srivastava, Etiena Basner-Tschakarjan, Federico Mingozzi, Katherine A. High, John T. Gray, Ulrike M. Reiss, Arthur W. Nienhuis, Andrew M. Davidoff",Gene therapy,10.1056/NEJMoa1108046,Articles%20database/nihms349232.pdf,,N Engl J Med,Single peripheral-vein infusion of scAAV2/8-LP1-hFIXco gave FIX levels of 2–11% in six patients; four discontinued prophylaxis. Transient aminotransferase elevations in high-dose patients associated with AAV8-capsid T cells were managed with short glucocorticoids.,,Yes,,Done,"In a phase 1/2 trial of six men with severe hemophilia B, a single peripheral-vein infusion of scAAV2/8-LP1-hFIXco produced sustained FIX activity of 2–11% of normal. Four patients stopped prophylaxis and bleeding improved. Two high-dose patients had transient ALT rises linked to capsid-specific T cells, controlled with short glucocorticoids without loss of FIX expression.",Clinical trial (Phase 1/2),2011
Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates,,"Immanuel P. Seitz, Fabian Wozar, Guy Alex Ochakovski, Felix F. Reichel, Sven Korte, Birgit Korbmacher, Barbara Wilhelm, Daniela Süsskind, Karl-Ulrich Bartz-Schmidt, M. Dominik Fischer, Tobias Peters",Ophthalmology / Toxicology,https://doi.org/10.1167/tvst.14.1.29,Articles%20database/tvst-14-1-29.pdf,,Translational Vision Science & Technology,Subretinal rAAV.hPDE6A was tolerated up to 5×10^11 vg in NHPs; 1×10^12 vg produced dose-limiting retinal atrophy and ERG changes. NOAEL 5×10^11 vg; clinical starting dose selected as 5×10^10 vg.,,Yes,,Done,"In cynomolgus macaques, subretinal rAAV2/8.hPDE6A at doses ≤5×10^11 vg was well tolerated with mild, transient inflammation. A high dose (1×10^12 vg) caused focal retinal atrophy and ERG abnormalities in some animals, deemed test-article related and adverse. NOAEL was 5×10^11 vg; clinical starting dose set at 5×10^10 vg.",Preclinical,2025
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency,,"S. Hacein-Bey-Abina, S.-Y. Pai, H.B. Gaspar, M. Armant, C.C. Berry, S. Blanche, J. Bleesing, J. Blondeau, H. de Boer, K.F. Buckland, L. Caccavelli, G. Cros, S. De Oliveira, K.S. Fernández, D. Guo, C.E. Harris, G. Hopkins, L.E. Lehmann, A. Lim, W.B. London, J.C.M. van der Loo, N. Malani, F. Male, P. Malik, M.A. Marinovic, A.-M. McNicol, D. Moshous, B. Neven, M. Oleastro, C. Picard, J. Ritz, C. Rivat, A. Schambach, K.L. Shaw, E.A. Sherman, L.E. Silberstein, E. Six, F. Touzot, A. Tsytsykova, J. Xu-Bayford, C. Baum, F.D. Bushman, A. Fischer, D.B. Kohn, A.H. Filipovich, L.D. Notarangelo, M. Cavazzana, D.A. Williams, A.J. Thrasher",Gene therapy (Immunology),10.1056/NEJMoa1404588,Articles%20database/nihms640300.pdf,,N Engl J Med,"SIN γ-retrovirus restored functional, polyclonal T-cell immunity in most SCID-X1 patients, resolved infections, and showed reduced integration clustering near LMO2, MECOM, CCND2 and other proto-oncogenes versus LTR-containing vectors; no leukemia to median 29 months.",,Yes,,Done,Phase 1/2 trials in nine boys with SCID-X1 using a self-inactivating (SIN) γ-retrovirus vector expressing IL2RG resulted in restoration of functional T-cell immunity in seven of eight surviving patients and resolution of infections. Integration-site analysis showed significantly less clustering near lymphoid proto-oncogenes than earlier LTR-intact vectors. No leukemia observed to median follow-up (~29 months); long-term safety still unknown.,Clinical trial (Phase 1/2),2014
Inhalation of SP-101 Followed by Inhaled Doxorubicin Results in Robust and Durable hCFTRDR Transgene Expression in the Airways of Wild-Type and Cystic Fibrosis Ferrets,,"Katherine J.D.A. Excoffon, Mark D. Smith, Lillian Falese, Robert Schulingkamp, Shen Lin, Madhu Mahankali, Poornima K.L. Narayan, Matthew R. Glatfelter, Maria P. Limberis, Eric Yuen, Roland Kolbeck",Gene therapy,10.1089/hum.2024.064,Articles%20database/excoffon-et-al-2024-inhalation-of-sp-101-followed-by-inhaled-doxorubicin-results-in-robust-and-durable-hcftrr.pdf,,Human Gene Therapy,"Inhaled SP-101 (AAV2.5T) reached the respiratory tract and, when followed by inhaled doxorubicin, produced robust, durable (≥13 weeks) hCFTRDR mRNA expression. CF mucus did not impede transduction. Neutralizing antibodies developed; T-cell responses were low.",,Yes,,Done,"Nebulized SP-101 (AAV2.5T carrying hCFTRDR) distributed across ferret airways. A single inhaled dose followed by inhaled doxorubicin markedly increased hCFTRDR mRNA (up to ~25-fold), with durable expression for at least 13 weeks. CF mucus did not block transduction. Binding and neutralizing antibodies formed; T-cell responses were minimal. Supports clinical development.",Preclinical (animal study),2024
Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome,,"Wen Y. Ding, Valeryia Kuzmuk, Sarah Hunter, Abigail Lay, Bryony Hayes, Matthew Beesley, Ruth Rollason, Jennifer A. Hurcombe, Fern Barrington, Catrin Masson, William Cathery, Carl May, Jack Tuffin, Timothy Roberts, Geraldine Mollet, Colin J. Chu, Jenny McIntosh, Richard J. Coward, Corinne Antignac, Amit Nathwani, Gavin I. Welsh, Moin A. Saleem",Nephrology / Gene therapy,10.1126/scitranslmed.abc8226,Articles%20database/scitranslmed.abc8226.pdf,,Science Translational Medicine,"AAV-LK03 efficiently transduces human podocytes; AAV2/9 delivers WT podocin in mouse NPHS2 models. Prophylactic and therapeutic AAV2/9 reduced proteinuria, improved plasma creatinine/urea/cholesterol, histology and survival, validating podocytes as an AAV gene-therapy target.",,Yes,,Done,"This preclinical study shows AAV-mediated gene therapy can target podocytes to rescue monogenic nephrotic syndrome. AAV-LK03 efficiently transduces human podocytes in vitro; AAV2/9 delivering WT podocin in inducible NPHS2 mouse models reduced albuminuria, improved plasma markers, histology and survival in prophylactic and therapeutic settings.",Preclinical,2023
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B,,"Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe",Gene therapy (Hematology),10.1182/bloodadvances.2019000811,Articles%20database/haemophilia_B_phase2B_study.pdf,,Blood Advances,"Single-dose etranacogene dezaparvovec (2×10^13 gc/kg) in 3 adults with severe/moderately severe hemophilia B achieved mean FIX 31% at 6 weeks and 47% at 26 weeks, complete bleed cessation and no FIX replacement up to 26 weeks, tolerated without corticosteroids, effective despite preexisting anti-AAV5 NAbs.",,Yes,,Done,"In a phase 2b open-label trial (n=3), a single IV dose of etranacogene dezaparvovec (2×10^13 gc/kg) produced mean FIX activity of 31% at 6 weeks and 47% at 26 weeks, eliminated bleeding and the need for FIX replacement through 26 weeks, was generally well tolerated, and was effective despite preexisting anti-AAV5 neutralizing antibodies.",Clinical trial (Phase 2b),2019
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A,,"Margareth C. Ozelo, Johnny Mahlangu, K. John Pasi, Adam Giermasz, Andrew D. Leavitt, Michael Laffan, Emily Symington, Doris V. Quon, Jiaan-Der Wang, Kathelijne Peerlinck, Steven W. Pipe, Bella Madan, Nigel S. Key, Glenn F. Pierce, Brian O’Mahony, Radoslaw Kaczmarek, Joshua Henshaw, Adebayo Lawal, Kala Jayaram, Mei Huang, Xinqun Yang, Wing Y. Wong, Benjamin Kim",Hematology/Gene therapy,10.1056/NEJMoa2113708,Articles%20database/haemophilia_A_phase3_study.pdf,,The New England Journal of Medicine,"Single infusion of valoctocogene roxaparvovec raised factor VIII activity (mean +41.9 IU/dL), cut factor VIII use by 98.6% and treated bleeds by 83.8%; ALT elevations frequent and treated with immunosuppression; no inhibitors or thrombosis.",,Yes,,Done,"Phase 3 open-label study: single infusion of valoctocogene roxaparvovec (6×10^13 vg/kg) in men with severe hemophilia A increased endogenous FVIII (mean +41.9 IU/dL at weeks 49–52), reduced annual FVIII concentrate use by 98.6% and treated bleeding by 83.8%. ALT elevations were common but managed with immunosuppression; no FVIII inhibitors or thrombosis observed.",Clinical trial (Phase 3),2022
"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial",,"Stephen Russell, Jean Bennett, Jennifer A Wellman, Daniel C Chung, Zi-Fan Yu, Amy Tillman, Janet Wittes, Julie Pappas, Okan Elci, Sarah McCague, Dominique Cross, Kathleen A Marshall, Jean Walshire, Taylor L Kehoe, Hannah Reichert, Maria Davis, Leslie Raffini, Lindsey A George, F Parker Hudson, Laura Dingfield, Xiaosong Zhu, Julia A Haller, Elliott H Sohn, Vinit B Mahajan, Wanda Pfeifer, Michelle Weckmann, Chris Johnson, Dina Gewaily, Arlene Drack, Edwin Stone, Katie Wachtel, Francesca Simonelli, Bart P Leroy, J Fraser Wright, Katherine A High, Albert M Maguire",Gene therapy / Ophthalmology,10.1016/S0140-6736(17)31868-8,Articles%20database/retinal_dystrophy_phase3.pdf,,Lancet,"Phase 3 RCT: bilateral subretinal voretigene neparvovec improved MLMT (mean change 1.8 vs 0.2; p=0.0013), FST (>2 log units), and visual fields at 1 year; 65% passed MLMT at 1 lux. No product-related serious adverse events.",,Yes,,Done,Phase 3 randomized open-label trial showed bilateral subretinal voretigene neparvovec improved functional vision in biallelic RPE65-mediated inherited retinal dystrophy. At 1 year mean MLMT change was 1.8 vs 0.2 (p=0.0013); FST improved >2 log units. 65% of treated passed MLMT at 1 lux. No product-related serious adverse events observed.,Clinical trial,2017
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy,,"Jerry R. Mendell, Samiah Al-Zaidy, Richard Shell, W. Dave Arnold, Louise R. Rodino-Klapac, Thomas W. Prior, Linda Lowes, Lindsay Alfano, Katherine Berry, Kathleen Church, John T. Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Jessica A. Cardenas, Marjet D. Heitzer, Allan Kaspar, Sarah Corcoran, Lyndsey Braun, Shibi Likhite, Carlos Miranda, Kathrin Meyer, K.D. Foust, Arthur H.M. Burghes, Brian K. Kaspar",Neurology/Gene therapy,10.1056/NEJMoa1706198,Articles%20database/NEJMoa1706198.pdf,,The New England Journal of Medicine,"Single IV AAV9-SMN in 15 SMA1 infants led to prolonged event-free survival vs historical cohorts, major motor milestone gains and CHOP INTEND score improvements in high-dose patients; transient liver enzyme elevations were attenuated by prednisolone.",,Yes,,Done,"In 15 infants with SMA type 1, a single IV infusion of AAV9 delivering SMN1 (AVXS-101) was safe and associated with markedly improved event-free survival versus historical cohorts, substantial increases in CHOP INTEND scores, and attainment of major motor milestones in the high-dose group; transient aminotransferase elevations were managed with prednisolone.",Clinical trial,2017
Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial,,"William W. Hauswirth, Tomas S. Aleman, Shalesh Kaushal, Artur V. Cideciyan, Sharon B. Schwartz, Lili Wang, Thomas J. Conlon, Sanford L. Boye, Terence R. Flotte, Barry J. Byrne, Samuel G. Jacobson",Gene therapy (Ophthalmology),10.1089/hum.2008.107,Articles%20database/2008-treatment-of-leber-congenital-amaurosis-due-to-rpe65-mutations-by-ocular-subretinal-injection-of-adeno-associated.pdf,,Human Gene Therapy,Subretinal rAAV2-RPE65 in three RPE65-LCA patients was safe short-term with no systemic toxicity; treated eyes had significant improvements in dark-adapted sensitivity (p<0.001) and patient-reported improved dim-light vision; visual acuity unchanged; one case of foveal thinning.,,Yes,,Done,Phase I trial of subretinal rAAV2-CB-SB-hRPE65 in three adults with RPE65-associated Leber congenital amaurosis. No vector-related serious adverse events or systemic toxicity observed. Visual acuity unchanged overall; all patients reported improved vision in low light and treated eyes showed significant increases in dark-adapted sensitivity (p<0.001). One patient had foveal thinning.,Clinical trial (Phase I),2008
"Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital Amaurosis",,"Samuel G. Jacobson, Sanford L. Boye, Tomas S. Aleman, Thomas J. Conlon, Caroline J. Zeiss, Alejandro J. Roman, Artur V. Cideciyan, Sharon B. Schwartz, Andras M. Komaromy, Michelle Doobrajh, Andy Y. Cheung, Alexander Sumaroka, Susan E. Pearce-Kelling, Gustavo D. Aguirre, Shalesh Kaushal, Albert M. Maguire, Terence R. Flotte, William W. Hauswirth",Gene therapy (Ophthalmology),,Articles%20database/2006-safety-in-nonhuman-primates-of-ocular-aav2-rpe65-a-candidate-treatment-for-blindness-in-leber-congenital-amaurosis.pdf,,Human Gene Therapy,No systemic toxicity; transient ocular inflammation resolving by 1 week; ERG responses unchanged at 3 months; healed retinal perforations from subretinal injections; vector DNA detected in injected retina/vitreous/optic nerve at 1 week but not in optic nerve/brain at 3 months.,,Yes,,Done,"GLP preclinical safety study of subretinal AAV2-RPE65 in 17 cynomolgus monkeys. No systemic toxicity observed; transient ocular inflammation resolved by 1 week. ERG measurements at 3 months showed no treatment-related functional loss. Surgical retinotomy sites healed; limited, transient vector biodistribution to injected eye and optic nerve. Results support consideration of an upper no-observed-adverse-effect dose for human trials.",Preclinical,2006
Gene Therapy for Leber Congenital Amaurosis caused by RPE65 mutations: Safety and Efficacy in Fifteen Children and Adults Followed up to Three Years,,"Samuel G. Jacobson, Artur V. Cideciyan, Ramakrishna Ratnakaram, Elise Heon, Sharon B. Schwartz, Alejandro J. Roman, Marc C. Peden, Tomas S. Aleman, Sanford L. Boye, Alexander Sumaroka, Thomas J. Conlon, Roberto Calcedo, Ji-jing Pang, Kirsten E. Erger, Melani B. Olivares, Cristina L. Mullins, Malgorzata Swider, Shalesh Kaushal, Willam J. Feuer, Alessandro Iannaccone, Gerald A. Fishman, Edwin M. Stone, Barry J. Byrne, William W. Hauswirth",Ophthalmology (Gene therapy),10.1001/archophthalmol.2011.298,Articles%20database/nihms-380089.pdf,,Archives of Ophthalmology (Arch Ophthalmol),Phase I subretinal rAAV2-hRPE65 in 15 patients: no systemic toxicity; significant rod and cone sensitivity gains localized to treated areas; extrafoveal treatment efficacious; foveal injections risk retinal thinning and acuity loss; no age-dependent effects.,,Yes,,Done,"Open-label, dose-escalation Phase I trial of subretinal rAAV2-hRPE65 in 15 patients (ages 11–30) showed no systemic toxicity; ocular adverse events were surgical. Treated eyes had significant increases in rod and cone sensitivity (FST, TPLR) localized to injection sites. Extrafoveal retina benefited; foveal injections carried risk of thinning and acuity loss. No age-dependent effect observed.",Clinical trial (Phase I),2012
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis,,"James W.B. Bainbridge, Manjit S. Mehat, Venki Sundaram, Scott J. Robbie, Susie E. Barker, Caterina Ripamonti, Anastasios Georgiadis, Freya M. Mowat, Stuart G. Beattie, Peter J. Gardner, Kecia L. Feathers, Vy A. Luong, Suzanne Yzer, Kamaljit Balaggan, Ananth Viswanathan, Thomy J.L. de Ravel, Ingele Casteels, Graham E. Holder, Nick Tyler, Fred W. Fitzke, Richard G. Weleber, Marko Nardini, Anthony T. Moore, Debra A. Thompson, Simon M. Petersen-Jones, Michel Michaelides, L. Ingeborgh van den Born, Andrew Stockman, Alexander J. Smith, Gary Rubin, Robin R. Ali",Ophthalmology (Gene therapy),10.1056/NEJMoa1414221,Articles%20database/NEJMoa1414221.pdf,,The New England Journal of Medicine,"Subretinal rAAV2/2.RPE65 produced modest, temporary improvements in retinal sensitivity in some patients (peak 6–12 months), no ERG recovery, dose-related inflammatory events at higher doses; dog studies showed strong dose-dependent ERG/vision gains and higher human RPE65 demand.",,Yes,,Done,"Phase 1–2 open-label trial of subretinal rAAV2/2.RPE65 in 12 patients with RPE65-related Leber’s congenital amaurosis showed modest, dose-related improvements in retinal sensitivity in six participants (peaking at 6–12 months and then declining). No ERG-detected recovery in humans; higher doses caused intraocular inflammation and some vision loss. Parallel dog studies showed dose-dependent ERG and vision gains and indicate higher RPE65 demand in humans.",Clinical trial (Phase 1–2 open-label),2015
Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood–Onset Retinal Dystrophy,,"Richard G. Weleber, Mark E. Pennesi, David J. Wilson, Shalesh Kaushal, Laura R. Erker, Lauren Jensen, Maureen T. McBride, Terence R. Flotte, Margaret Humphries, Roberto Calcedo, William W. Hauswirth, Jeffrey D. Chulay, J. Timothy Stout",Gene therapy / Ophthalmology,10.1016/j.ophtha.2016.03.003,Articles%20database/1-s2.0-S0161642016003390-main.pdf,,Ophthalmology,"Subretinal rAAV2-CB-hRPE65 was well tolerated in 12 patients; no treatment-related serious adverse events. Improvements in ≥1 visual function measure occurred in 9/12 patients, with greatest acuity gains in younger patients. Longer follow-up required.",,Yes,,Done,Phase 1/2 open-label trial of subretinal rAAV2-CB-hRPE65 in 12 patients (ages 6–39) showed acceptable safety with no treatment-related serious adverse events. Improvements in one or more visual measures were observed in 9/12 patients; younger patients with better baseline acuity had the greatest BCVA gains. Longer follow-up and more patients needed.,Clinical trial (Phase 1/2 nonrandomized multicenter),2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial,,"Jean Bennett, Jennifer Wellman, Kathleen A Marshall, Sarah McCague, Manzar Ashtari, Julie DiStefano-Pappas, Okan U Elci, Daniel C Chung, Junwei Sun, J Fraser Wright, Dominique R Cross, Puya Aravand, Laura L Cyckowski, Jeannette L Bennicelli, Federico Mingozzi, Alberto Auricchio, Eric A Pierce, Jason Ruggiero, Bart P Leroy, Francesca Simonelli, Katherine A High, Albert M Maguire",Ophthalmology (Gene therapy),10.1016/S0140-6736(16)30371-3,Articles%20database/1-s2.0-S0140673616303713-main.pdf,,Lancet,"Contralateral subretinal AAV2-hRPE65v2 was well tolerated; pooled gains in mobility and full-field light sensitivity appeared by day 30 and persisted to year 3 with minimal immune responses, representing the first successful gene therapy readministration to the second eye.",,Yes,,Done,"Follow-on phase 1 trial of subretinal AAV2-hRPE65v2 to the contralateral eye in 11 patients (10 analyzed) showed no AAV-related adverse events, minimal immunogenicity, and durable improvements in mobility and full-field light sensitivity by day 30 that persisted to 3 years. Supports safety and efficacy of bilateral retinal gene therapy.",Phase 1 clinical trial (follow-on),2016
Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer,,"Jeannette Bennicelli, John Fraser Wright, Andras Komaromy, Jonathan B Jacobs, Bernd Hauck, Olga Zelenaia, Federico Mingozzi, Daniel Hui, Daniel Chung, Tonia S Rex, Zhangyong Wei, Guang Qu, Shangzhen Zhou, Caroline Zeiss, Valder R Arruda, Gregory M Acland, Lou F Dell’Osso, Katherine A High, Albert M Maguire, Jean Bennett",Gene therapy (Ophthalmology),doi:10.1038/sj.mt.6300389,Articles%20database/1-s2.0-S1525001616314174-main.pdf,,Molecular Therapy,"Optimized AAV2.RPE65 (modified Kozak, long stuffer, PF68) restored retinal function and vision in Rpe65-deficient mice and dogs within 2–5 weeks, with minimal toxicity and transient anti-AAV2 antibodies.",,Yes,,Done,"Optimized AAV2.RPE65 (modified Kozak, long stuffer sequence, and PF68 surfactant) enabled efficient RPE transduction and restored ERG responses and visual acuity in Rpe65-deficient mice and dogs within weeks. Treatment was well tolerated with minimal retinal toxicity; transient anti-AAV2 humoral responses were observed. The vector shows promise for treating RPE65-related LCA.",Preclinical,2008
Muscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping,,"Adeline Vulin, Inès Barthélémy, Aurélie Goyenvalle, Jean-Laurent Thibaud, Cyriaque Beley, Graziella Griffith, Rachid Benchaouir, Maëva le Hir, Yves Unterfinger, Stéphanie Lorain, Patrick Dreyfus, Thomas Voit, Pierre Carlier, Stéphane Blot, Luis Garcia",Gene therapy,10.1038/mt.2012.181,Articles%20database/PIIS1525001616322134.pdf,,Molecular Therapy,"AAV1-U7-mediated exon skipping in GRMD dogs restored truncated dystrophin and its glycoprotein complex, improved muscle architecture and strength, reduced calcium overload and MRI markers; expression persisted but progressively declined over 5 years without evident immune rejection, suggesting recurrent treatments may be required.",,Yes,,Done,"In GRMD dogs, AAV1 vectors delivering engineered U7 snRNAs to skip exons 6 and 8 restored an in-frame truncated dystrophin, reconstituted the dystrophin-glycoprotein complex, reduced calcium-overloaded fibers, improved MRI indices and tetanic muscle force. Expression persisted but declined over five years without clear immune rejection, indicating benefit but likely need for repeated treatment.",Preclinical,2012
Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient Dogs,,"Joe N Kornegay, Juan Li, Janet R Bogan, Daniel J Bogan, Chunlian Chen, Hui Zheng, Bing Wang, Chunping Qiao, James F Howard Jr, Xiao Xiao",Gene therapy,10.1038/mt.2010.94,Articles%20database/PIIS1525001616311017.pdf,,Molecular Therapy,"IV AAV9 encoding codon-optimized human mini-dystrophin in neonatal GRMD dogs yielded widespread muscle expression (15–~100% fibers) by 16 weeks but induced early inflammation with pelvic limb atrophy/contractures; high dose, CMV promoter, and human protein likely contributors.",,Yes,,Done,"Systemic IV delivery of AAV9 carrying a codon-optimized human mini-dystrophin in 4-day-old GRMD dogs produced widespread muscle transduction (≈15% to ~100% positive myofibers in various muscles) by 16 weeks. However, treated dogs developed early inflammatory changes, pelvic limb atrophy and contractures, implicating high vector dose, CMV promoter, and human transgene as safety concerns.",Preclinical,2010
Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog,,"Taeyoung Koo, Takashi Okada, Takis Athanasopoulos, Helen Foster, Shin’ichi Takeda, George Dickson",Gene therapy,10.1002/jgm.1602,Articles%20database/The_Journal_of_Gene_Medicine_-_2011_-_Koo_-_Longterm_functional_adenoassociated_virusmicrodystrophin_expression_in_the.pdf,,The Journal of Gene Medicine,"Single intramuscular AAV2/8 delivering mRNA-optimized canine microdystrophin yielded high, stable expression in CXMDj muscle for at least 8 weeks, restored DPC, improved membrane integrity and reduced regeneration and CD8+ infiltration.",,Yes,,Done,"Intramuscular delivery of an AAV2/8 vector encoding a species-specific, mRNA sequence-optimized canine microdystrophin (cMD1) under a muscle-specific promoter produced robust, widespread and stable dystrophin expression in a CXMDj dog for ≥8 weeks, restored dystrophin-associated protein complex, reduced membrane permeability and central nucleation, and showed minimal CD8+ T-cell infiltration, supporting further development of AAV gene therapy for DMD.",Preclinical,2011
Sustained AAV-mediated Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy with a Brief Course of Immunosuppression,,"Zejing Wang, Christian S Kuhr, James M Allen, Michael Blankinship, Paul Gregorevic, Jeffrey S Chamberlain, Stephen J Tapscott, Rainer Storb",Gene therapy,doi:10.1038/sj.mt.6300161,Articles%20database/PIIS1525001616316756.pdf,,Molecular Therapy,"A brief course of ATG+CSP+MMF permitted long-term AAV6-mediated canine micro-dystrophin expression in cxmd dogs, restored dystrophin-associated glycoprotein complex localization, and persisted months after immunosuppression withdrawal.",,Yes,,Done,"In a canine DMD model, a short immunosuppressive regimen (anti-thymocyte globulin, cyclosporine, mycophenolate mofetil) allowed prolonged AAV6-mediated expression of a canine micro-dystrophin transgene. Expression restored dystrophin-associated proteins at the sarcolemma and persisted for months after stopping immunosuppression, supporting clinical translation.",Preclinical,2007
Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model,,"Bing Wang, Juan Li, Xiao Xiao",Gene therapy,10.1073/pnas.240335297,Articles%20database/pq013714.pdf,,Proceedings of the National Academy of Sciences (PNAS),"AAV-delivered human minidystrophin (<4.2 kb) restores dystrophin and DAP complexes, prevents/reverses dystrophic pathology in mdx mice, normalizes myofiber morphology and membrane integrity, and shows long-term efficacy.",,Yes,,Done,"Human minidystrophin genes (<4.2 kb) were packaged into AAV vectors and injected into mdx mice. This yielded efficient, stable expression in most myofibers, restored dystrophin and dystrophin-associated protein complexes, prevented or reversed dystrophic pathology, and preserved membrane integrity, supporting AAV-mediated gene therapy for DMD.",Preclinical,2000
Adeno-Associated Virus Vector-Mediated Minidystrophin Gene Therapy Improves Dystrophic Muscle Contractile Function in mdx Mice,,"Jon Watchko, Terry O’Day, Bing Wang, Liqiao Zhou, Ying Tang, Juan Li, Xiao Xiao",Gene therapy,,Articles%20database/2004-adeno-associated-virus-vector-mediated-minidystrophin-gene-therapy-improves-dystrophic-muscle-contractile-function.pdf,,HUMAN GENE THERAPY,"AAV–minidystrophin (AAV-MCK-3990) injected into adult mdx TA muscles led to sustained expression, significantly higher P0/CSA and greater resistance to lengthening activation-induced force decrements versus untreated mdx, suggesting effective functional rescue in this preclinical model.",,Yes,,Done,"Intramuscular delivery of an AAV vector (AAV-MCK-3990) encoding a human minidystrophin into tibialis anterior muscles of adult mdx mice produced sustained minidystrophin expression (30–60% fibers), increased isometric force generation and improved resistance to lengthening activation-induced force loss, supporting AAV–minidystrophin as a potential DMD therapy.",Preclinical,2002
rAAV-CFTRDR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice,,"Dragana Vidović, Marianne S. Carlon, Mélanie F. da Cunha, Johanna F. Dekkers, Monika I. Hollenhorst, Marcel J. C. Bijvelds, Anabela S. Ramalho, Chris Van den Haute, Marc Ferrante, Veerle Baekelandt, Hettie M. Janssens, Kris De Boeck, Isabelle Sermet-Gaudelus, Hugo R. de Jonge, Rik Gijsbers, Jeffrey M. Beekman, Aleksander Edelman, Zeger Debyser",Gene therapy,10.1164/rccm.201505-0914OC,Articles%20database/Vidovi.pdf,,American Journal of Respiratory and Critical Care Medicine,"rAAV2/5-CFTRDR restores chloride and fluid secretion in CF patient-derived intestinal organoids and corrects nasal ion transport in DF508 mice after a single dose, supporting clinical potential of rAAV-mediated CFTR gene therapy.",,Yes,,Done,"Using an rAAV2/5 vector encoding a truncated CFTR (CFTRDR) under a short CMV173 promoter, a single dose restored CFTR function in patient-derived intestinal organoids (forskolin-induced swelling) and improved nasal ion transport in DF508 CF mice (nasal PD). Results demonstrate preclinical efficacy and support further development of rAAV-CFTRDR gene therapy.",Preclinical,2016
Recovery of Airway Cystic Fibrosis Transmembrane Conductance Regulator Function in Mice with Cystic Fibrosis After Single-Dose Lentivirus-Mediated Gene Transfer,,"Maria Limberis, Donald S. Anson, Maria Fuller, David W. Parsons",Gene therapy,,Articles%20database/2004-recovery-of-airway-cystic-fibrosis-transmembrane-conductance-regulator-function-in-mice-with-cystic-fibrosis-after.pdf,,Human Gene Therapy,Single-dose lentiviral CFTR delivery after LPC airway conditioning produced persistent transgene expression and partial electrophysiologic correction in cftr knockout mice for up to 110 days; LPC enhanced transfer while Polybrene inhibited in vivo transduction.,,Yes,,Done,Airway pretreatment with lysophosphatidylcholine (LPC) combined with a VSV-G–pseudotyped HIV-derived lentiviral vector produced persistent LacZ expression in mouse nasal epithelium for ≥92 days. Lentiviral delivery of CFTR yielded partial electrophysiologic correction in cftr(tm1Unc) mice for at least 110 days. Polybrene reduced in vivo transduction. Findings support LPC conditioning plus lentivirus for sustained airway CFTR gene transfer.,Preclinical,2002
Complete Rescue of Lipoprotein Lipase–Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation,,"Colin J.D. Ross, Guoqing Liu, Jan Albert Kuivenhoven, Jaap Twisk, Jaap Rip, Willemijn van Dop, Katherine J.D. Ashbourne Excoffon, Suzanne M.E. Lewis, John J. Kastelein, Michael R. Hayden",Gene therapy,10.1161/01.ATV.0000176971.27302.b0,Articles%20database/ross-et-al-2005-complete-rescue-of-lipoprotein-lipase-deficient-mice-by-somatic-gene-transfer-of-the-naturally.pdf,,Arterioscler Thromb Vasc Biol.,"Ad-LPL S447X rescued 95% of LPL−/− mice to adulthood, increased LPL catalytic activity ~2.1-fold vs LPL WT, reduced plasma TG by ~99% in neonates and markedly increased HDL-C, indicating S447X is a beneficial gain-of-function mutation improving TG clearance.",,Yes,,Done,"Adenoviral-mediated delivery of human LPL S447X to LPL−/− mice rescued 95% of neonates to adulthood, increased postheparin LPL catalytic activity ~2.1–2.2-fold versus wild-type, reduced plasma triglycerides up to 99% and increased HDL-C, demonstrating S447X is a gain-of-function variant that enhances TG clearance.",Preclinical,2005
Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation,,"COLIN J.D. ROSS, JAAP TWISK, ANDREW C. BAKKER, FUDAN MIAO, DENNIS VERBART, JAAP RIP, TAMARA GODBEY, PAUL DIJKHUIZEN, WIM T.J.M.C. HERMENS, JOHN J.P. KASTELEIN, JAN ALBERT KUIVENHOVEN, JANNEKE M. MEULENBERG, MICHAEL R. HAYDEN",Gene therapy,,Articles%20database/2006-correction-of-feline-lipoprotein-lipase-deficiency-with-adeno-associated-virus-serotype-1-mediated-gene-transfer.pdf,,Human Gene Therapy,Single IM AAV1-LPL S447X rapidly normalized plasma TGs in LPL-deficient cats (up to ~99.9% reduction). Efficacy was transient from anti-hLPL immunity; cyclophosphamide prolonged effects at low dose. Supports feasibility for human LPL gene therapy.,,Yes,,Done,"Intramuscular AAV1-mediated delivery of human LPL S447X in LPL-deficient cats produced rapid, dose-dependent normalization of severe hypertriglyceridemia (up to ~99–99.9% reduction). Efficacy was transient due to anti-hLPL immune responses; cyclophosphamide immunosuppression prolonged benefit at low vector doses. Results support feasibility of muscle-directed LPL gene therapy.",Preclinical,2006
Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation,,"Colin J.D. Ross, Jaap Twisk, Janneke M. Meulenberg, Guoqing Liu, Karin van den Oever, Ewoud Moraal, Wim T. Hermens, Jaap Rip, John J.P. Kastelein, Jan Albert Kuivenhoven, Michael R. Hayden",Gene therapy,,Articles%20database/2004-long-term-correction-of-murine-lipoprotein-lipase-deficiency-with-aav1-mediated-gene-transfer-of-the-naturally.pdf,,Human Gene Therapy,"Single IM AAV1-LPL S447X yielded dose-dependent LPL expression, near-normalization of plasma TG and HDL-C within 1 week, reversal of muscle abnormalities, efficient fat-load clearance, and sustained effects for over a year in LPL−/− mice.",,Yes,,Done,"In LPL-deficient mice, intramuscular AAV1-mediated delivery of human LPL S447X produced dose-dependent LPL expression, normalized plasma triglycerides and increased HDL-C within one week, corrected muscle pathology, improved postprandial TG clearance, and provided durable benefit for >1 year.",Preclinical,2004
Gene Therapy Successfully Delays Degeneration in a Mouse Model of PDE6A-Linked Retinitis Pigmentosa (RP43),,"Christian Schön, Vithiyanjali Sothilingam, Regine Mühlfriedel, Marina Garcia Garrido, Susanne C. Beck, Naoyuki Tanimoto, Bernd Wissinger, François Paquet-Durand, Martin Biel, Stylianos Michalakis, Mathias W. Seeliger, RD-Cure Consortium",Gene therapy (Ophthalmology),10.1089/hum.2017.156,Articles%20database/gene-therapy-successfully-delays-degeneration-in-a-mouse-model-of-pde6a-linked-retinitis-pigmentosa-(rp43).pdf,,Human Gene Therapy,"rAAV8.PDE6A drives stable human PDE6A expression in murine rods, preserves ONL thickness and outer segment structure, prevents retinal detachment, prolongs cone survival up to 6 months, and restores cone-driven retinal function — proof-of-concept for translation.",,Yes,,Done,"Subretinal delivery of an rAAV8 vector encoding human PDE6A in Pde6a D670G mice produced stable PDE6A expression in rods, preserved outer nuclear layer thickness and rod outer segments, prevented retinal detachment, prolonged cone survival for at least 6 months, and restored cone-driven ERG signals, supporting translational potential.",Preclinical,2017
"Gene Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal Morphology in Dogs, Leading the Way Toward Treating Human PDE6A-Retinitis Pigmentosa",,"Laurence M. Occelli, Christian Schön, Mathias W. Seeliger, Martin Biel, Stylianos Michalakis, Simon M. Petersen-Jones, RD-CURE Consortium",Gene therapy,10.1089/hum.2017.155,Articles%20database/gene-supplementation-rescues-rod-function-and-preserves-photoreceptor-and-retinal-morphology-in-dogs-leading-the-way.pdf,,Human Gene Therapy,"AAV8-hRHO-PDE6A subretinal gene supplementation in Pde6a−/− dogs restored rod vision, improved ERGs at higher dose, preserved photoreceptor thickness and morphology, normalized PDE6B and cGMP levels, and improved cone structure—advancing toward human trials.",,Yes,,Done,"AAV8-mediated subretinal delivery of human PDE6A (hRHO-PDE6A) in Pde6a−/− dogs restored rod-mediated vision, produced ERG improvement at higher doses, preserved photoreceptor (REC+) thickness and morphology, normalized PDE6B expression and reduced cGMP accumulation, and improved cone structure—supporting translation toward human PDE6A-RP trials.",Preclinical,2017
Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa,,"Freya M. Mowat, Laurence M. Occelli, Joshua T. Bartoe, Kristen J. Gervais, Ashlee R. Bruewer, Janice Querubin, Astra Dinculescu, Sanford L. Boye, William W. Hauswirth, Simon M. Petersen-Jones",Gene therapy / Ophthalmology,10.3389/fnins.2017.00342,Articles%20database/fnins-11-00342.pdf,,Frontiers in Neuroscience,"AAV8(Y733F)-mediated PDE6A gene augmentation in Pde6a mutant dogs restored PDE6 expression, yielded rod function and improved dim-light vision, preserved photoreceptors and reduced cGMP/rhodopsin mislocalization, but caused focal retinal lesions/rosettes.",,Yes,,Done,"Subretinal delivery of AAV8(Y733F) encoding canine PDE6A to Pde6a mutant dogs restored PDE6 in rod outer segments, produced measurable rod function (scotopic threshold response) and improved dim-light vision, preserved photoreceptors and reduced cGMP/rhodopsin mislocalization. Some treatment-related retinal lesions and rosettes occurred; further optimization required.",Preclinical,2017
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa,,"Katherine J. Wert, Richard J. Davis, Javier Sancho-Pelluz, Patsy M. Nishina, Stephen H. Tsang",Gene therapy,10.1093/hmg/dds466,Articles%20database/dds466.pdf,,Human Molecular Genetics,"A single subretinal injection of AAV2/8(Y733F)-Rho-Pde6a in Pde6a nmf363 mice increased PDE6a and RHO, preserved photoreceptors and OS locally, delayed RPE atrophy, and maintained rod/cone ERG function for ≥6 months, indicating treatability of PDE6a-linked RP by gene therapy.",,Yes,,Done,"Subretinal delivery of AAV2/8(Y733F)-Rho-Pde6a to Pde6a nmf363 mice restored PDE6a and rhodopsin expression, preserved photoreceptor cell bodies and outer segments near the injection site, delayed RPE atrophy, and maintained rod and cone ERG responses for at least 6 months, supporting gene therapy for PDE6a-related RP.",Preclinical,2013
Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial,,"Albert M Maguire, Katherine A High, Alberto Auricchio, J Fraser Wright, Eric A Pierce, Francesco Testa, Federico Mingozzi, Jeannette L Bennicelli, Gui-shuang Ying, Settimio Rossi, Ann Fulton, Kathleen A Marshall, Sandro Banfi, Daniel C Chung, Jessica I W Morgan, Bernd Hauck, Olga Zelenaia, Xiaosong Zhu, Leslie Raffini, Frauke Coppieters, Elfride De Baere, Kenneth S Shindler, Nicholas J Volpe, Enrico M Surace, Carmela Acerra, Arkady Lyubarsky, T Michael Redmond, Edwin Stone, Junwei Sun, Jennifer Wellman McDonnell, Bart P Leroy, Francesca Simonelli, Jean Bennett",Ophthalmology (Gene therapy),10.1016/S0140-6736(09)61836-5,Articles%20database/1-s2.0-S0140673609618365-main.pdf,,The Lancet,"In 12 patients treated with subretinal AAV2-hRPE65v2, therapy was safe and produced sustained improvements in pupillometry, visual fields, dark adaptation and ambulation; children had the largest gains, supporting early intervention.",,Yes,,Done,"Phase 1 dose-escalation trial of subretinal AAV2-hRPE65v2 in 12 patients (ages 8–44) with RPE65-associated Leber's congenital amaurosis. Treatment was well tolerated and produced sustained objective and subjective improvements in retinal function; children showed the greatest gains, gaining ambulatory vision. Early intervention provided best outcomes.",Clinical trial (Phase 1),2009
HIGH THROUGHPUT RNA INTERFERENCE BASED SCREEN FOR THE IDENTIFICATION OF GENES IMPLICATED IN LISTERIA MONOCYTOGENES INFECTION,,Asongwe Lionel Ateh Tantoh,Infectious Diseases / Functional Genomics,,Articles%20database/thesis_hsf_2014_tantoh_ala.pdf,,"PhD thesis, University of Cape Town","Developed high-density siRNA arrays for reverse transfection; screened 3,150 human genes in 47,250 experiments across 15 replicates; identified 65 candidate host factors and validated 15 hits (notably BAHD1, INPP5B, LATS2), offering a scalable platform for host-targeted anti-Listeria strategies.",,Yes,,Done,"PhD thesis describing development of a miniaturized high-density siRNA reverse-transfection array and image-based screening pipeline to identify human host factors required for Listeria monocytogenes infection. The kinome/phosphatome/ubiquitome/protease subset (≈3,150 genes) was screened in 47,250 experiments; 65 candidates were found and 15 strong hits validated, including BAHD1, INPP5B and LATS2. The work provides a scalable, lower-cost platform for functional genomics and host-targeted therapeutic discovery.",Doctoral thesis (PhD),2014
Identification of Inhibitors of Inositol 5‑Phosphatases through Multiple Screening Strategies,,"Michelle Pirruccello, Ramiro Nandez, Olof Idevall-Hagren, Abel Alcazar-Roman, Laura Abriola, Shana Alexandra Berwick, Louise Lucast, Dayna Morel, Pietro De Camilli",Drug discovery,10.1021/cb500161z,Articles%20database/identification-of-inhibitors-of-inositol-5-phosphatases-through-multiple-screening-strategies.pdf,,ACS Chemical Biology,"Two main scaffold classes found: Class I (OCRL/INPP5B-selective; lead YU142670 binds INPP5B catalytic domain) and Class II (pan-5-phosphatase, toxic). YU142670 increases PI(4,5)P2, enhances actin nucleation, and inhibits OCRL activity in cells.",,Yes,,Done,"Developed three complementary high-throughput in vitro assays to screen for small-molecule modulators of inositol 5-phosphatases. Identified two chemical scaffolds: a pan-5-phosphatase class and a scaffold selective for OCRL/INPP5B. Lead compound YU142670 binds the INPP5B catalytic domain, raises cellular PI(4,5)P2 and enhances cortical actin, validating cellular efficacy.",Preclinical,2014
A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2,,"Kevin M. Flanigan, Tatyana A. Vetter, Tabatha R. Simmons, Megan Iammarino, Emma C. Frair, Federica Rinaldi, Louis G. Chicoine, Johan Harris, John P. Cheatham, Sharon L. Cheatham, Brian Boe, Megan A. Waldrop, Deborah A. Zygmunt, Davin Packer, Paul T. Martin",Gene therapy,10.1016/j.omtm.2022.08.009,Articles%20database/1-s2.0-S232905012200119X-main.pdf,,Molecular Therapy: Methods & Clinical Development,"First-in-human ILI delivery of rAAVrh74.MCK.GALGT2 in two DMD patients induced muscle GALGT2 expression and glycosylation with no serious AEs; the younger, higher-dose patient improved in NSAA and 6MWT over 24 months, supporting preliminary safety at 1×10^14 vg/kg.",,Yes,,Done,"Phase I/IIa isolated limb infusion of rAAVrh74.MCK.GALGT2 in two boys with Duchenne muscular dystrophy was well tolerated with no serious adverse events. Post-treatment biopsies showed GALGT2 expression and muscle glycosylation. The younger, higher-dose subject (1×10^14 vg/kg) showed functional improvement and stabilization over 24 months; the older, lower-dose subject declined. Results indicate preliminary safety and suggest potential efficacy at higher dose.",Clinical trial (Phase I/IIa),2022
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial,,"Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda P. Lowes, Natalie F. Reash, Megan A. Iammarino, Lindsay N. Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Mark Hogan, Shufang Wang, Stefanie Mason, Eddie Darton, Louise R. Rodino-Klapac",Neurology / Gene therapy,10.1002/mus.27955,Articles%20database/Muscle_and_Nerve_-_2023_-_Mendell_-_Longterm_safety_and_functional_outcomes_of_delandistrogene_moxeparvovec_gene_therapy.pdf,,Muscle & Nerve,"Single IV dose was well tolerated; all treatment-related AEs occurred within 70 days and resolved. Mean NSAA increased +7.0 at 4 years and showed a significant, clinically meaningful improvement vs propensity-weighted external control (LSM diff 9.4; p=0.0125).",,Yes,,Done,"In this open-label phase 1/2a trial (n=4), a single IV infusion of delandistrogene moxeparvovec was well tolerated with treatment-related AEs that were mild/moderate and resolved within 70 days. Mean NSAA improved by +7.0 points at 4 years, with a significant benefit versus a propensity-score–weighted external control (LSM diff 9.4; p=0.0125), suggesting durable microdystrophin expression and sustained functional stabilization.",Clinical trial (Phase 1/2a nonrandomized),2024
"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial",,"Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello, Riccardo Masson, Odile Boespflug-Tanguy, Claudio Bruno, Stefania Corti, Aurore Daron, Nicolas Deconinck, Laurent Servais, Volker Straub, Haojun Ouyang, Deepa Chand, Sitra Tauscher-Wisniewski, Nuno Mendonca, Arseniy Lavrov, on behalf of the STR1VE-EU study group",Neurology,,Articles%20database/1-s2.0-S1474442221002519-main.pdf,,The Lancet Neurology,"Onasemnogene abeparvovec produced motor milestone gains and markedly improved ventilation-free survival vs natural history: 14/32 sat independently; 31/32 ventilation-free at 14 months. Common AEs: pyrexia, URTI, elevated ALT. No new safety signals.",,Yes,,Done,"STR1VE-EU (phase 3) showed onasemnogene abeparvovec improved outcomes in symptomatic infants with SMA type 1: 44% (14/32) achieved independent sitting vs 0 in matched natural history; 97% (31/32) survived free from permanent ventilation at 14 months. Adverse events were common, including elevated liver enzymes; no new safety signals and benefit–risk deemed favourable.",Clinical trial (Phase 3 open-label single-arm),2021
"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)",,"Richard S. Finkel, Basil T. Darras, Jerry R. Mendell, John W. Day, Nancy L. Kuntz, Anne M. Connolly, Craig M. Zaidman, Thomas O. Crawford, Russell J. Butterfield, Perry B. Shieh, Gihan Tennekoon, John F. Brandsema, Susan T. Iannaccone, John Shoffner, Sarah Kavanagh, Thomas A. Macek, Sitra Tauscher-Wisniewski",Neurology,10.3233/JND-221560,Articles%20database/jnd-10-jnd221560.pdf,,Journal of Neuromuscular Diseases,"Intrathecal onasemnogene abeparvovec was safe and well-tolerated; medium dose gave significant HFMSE gains in 24–<60 month patients vs PNCR (LS mean diff 5.5, P<0.01). Younger group failed primary standing endpoint. AEs mostly Grade 1–2; no deaths.",,Yes,,Done,"Phase I STRONG (N=32) of intrathecal onasemnogene abeparvovec in sitting, nonambulatory SMA patients found the medium dose (1.2×10^14 vg) safe and generally well-tolerated. Older patients (24–<60 months) showed significant HFMSE improvements vs historic controls (P<0.01). Younger group did not meet the standing milestone. AEs were mostly mild; no deaths.",Phase I Clinical trial,2023
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial,,"Jerry R. Mendell, Francesco Muntoni, Craig M. McDonald, Eugenio M. Mercuri, Emma Ciafaloni, Hirofumi Komaki, Carmen Leon-Astudillo, Andrés Nascimento, Crystal Proud, Ulrike Schara-Schmidt, Aravindhan Veerapandiyan, Craig M. Zaidman, Maitea Guridi, Alexander P. Murphy, Carol Reid, Christoph Wandel, Damon R. Asher, Eddie Darton, Stefanie Mason, Rachael A. Potter, Teji Singh, Wenfei Zhang, Paulo Fontoura, Jacob S. Elkins, Louise R. Rodino-Klapac",Gene therapy (Neuromuscular disease),10.1038/s41591-024-03304-z,Articles%20database/s41591-024-03304-z.pdf,,Nature Medicine,"Primary endpoint not met: NSAA change at 52 weeks between-group difference 0.65 points (95% CI −0.45, 1.74; P=0.2441). Micro-dystrophin expression 34.29% vs 0% at week 12. Some secondary endpoints (TTR, 10MWR, SV95C) favored treatment; safety manageable; 11.1% had treatment-related SAEs.",,Yes,,Done,Phase 3 EMBARK trial of single-dose delandistrogene moxeparvovec in ambulatory males 4–<8 years with DMD did not meet the primary NSAA endpoint at 52 weeks. Treated patients showed micro-dystrophin expression (mean 34.29% at week 12) and some secondary functional measures numerically favored treatment. Safety was manageable; no deaths or discontinuations.,Clinical trial (Phase 3 randomized double-blind placebo-controlled),2024
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR),,"Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald, Kelly J. Lehman, Natalie L. Goedeker, Stefanie Mason, Alexander P. Murphy, Maitea Guridi, Shufang Wang, Carol Reid, Eddie Darton, Christoph Wandel, Sarah Lewis, Jyoti Malhotra, Danielle A. Griffin, Rachael A. Potter, Louise R. Rodino-Klapac, Jerry R. Mendell",Neurology,10.1002/ana.26755,Articles%20database/Annals_of_Neurology_-_2023_-_Zaidman_-_Delandistrogene_Moxeparvovec_Gene_Therapy_in_Ambulatory_Patients__Aged__4_to__8.pdf,,Annals of Neurology,"Robust muscle transduction with sarcolemmal micro-dystrophin at week 12; 1-year NSAA improved +4.0 and was significantly better than a propensity-weighted external natural history control (Δ+3.2, p<0.0001). Safety consistent with prior studies.",,Yes,,Done,"Open-label phase 1b study of 20 ambulatory boys (4–<8 y) given a single IV dose of delandistrogene moxeparvovec. At 12 weeks micro-dystrophin expression was robust with sarcolemmal localization; at 1 year motor function stabilized/improved (NSAA +4.0) versus external control (Δ+3.2, p<0.0001). Safety profile was consistent with prior trials.",Clinical trial (Phase 1b open-label single-arm),2023
Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study,,"Terence R. Flotte, Pamela L. Zeitlin, Thomas C. Reynolds, Alison E. Heald, Patty Pedersen, Suzanne Beck, Carol K. Conrad, Lois Brass-Ernst, Margaret Humphries, Kevin Sullivan, Randall Wetzel, George Taylor, Barrie J. Carter, William B. Guggino",Gene therapy (Cystic fibrosis),,Articles%20database/2004-phase-i-trial-of-intranasal-and-endobronchial-administration-of-a-recombinant-adeno-associated-virus-serotype-2.pdf,,Human Gene Therapy,"In 25 CF patients, intranasal and endobronchial rAAV2-CFTR was generally safe; minimal shedding; neutralizing antibodies in high-dose cohorts; DNA transfer seen only at highest doses with low copy numbers; supports further trials.",,Yes,,Done,Phase I study of intranasal and endobronchial rAAV2-CFTR in 25 CF patients found the vector generally safe across a wide dose range. Most adverse events were related to underlying CF or procedures. Minimal vector shedding occurred; high-dose subjects developed serum neutralizing antibodies. DNA transfer was detected only at highest doses at low copy numbers. Results support further clinical evaluation.,Clinical trial (Phase I),2003
Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial,,"RICHARD B. MOSS, CARLOS MILLA, JOHN COLOMBO, FRANK ACCURSO, PAMELA L. ZEITLIN, JOHN P. CLANCY, L. TERRY SPENCER, JOSEPH PILEWSKI, DAVID A. WALTZ, HENRY L. DORKIN, THOMAS FERKOL, MARK PIAN, BONNIE RAMSEY, BARRIE J. CARTER, DANA B. MARTIN, ALISON E. HEALD",Gene therapy,10.1089/hum.2007.022,Articles%20database/2007-repeated-aerosolized-aav-cftr-for-treatment-of-cystic-fibrosis-a-randomized-placebo-controlled-phase-2b-trial.pdf,,Human Gene Therapy,In this randomized Phase 2B trial (n=102) aerosolized tgAAVCF was safe and well tolerated but failed to improve FEV1 or sputum biomarkers versus placebo; AAV2 neutralizing titers rose. Further improvement of gene transfer vectors and endpoints is needed.,,Yes,,Done,"Randomized, double-blind Phase 2B trial of aerosolized tgAAVCF versus placebo in 102 CF patients. tgAAVCF was safe and well tolerated but did not produce a statistically significant improvement in FEV1 at 30 days or differences in serial lung function, sputum biomarkers, or antibiotic use. Further vector development and endpoint selection recommended.",Clinical trial (Randomized double-blind placebo-controlled Phase 2B),2007
AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient,,"James J. Dowling, Terry Pirovolakis, Keshini Devakandan, Ana Stosic, Mia Pidsadny, Elisa Nigro, Mustafa Sahin, Darius Ebrahimi-Fakhari, Souad Messahel, Ganapathy Varadarajan, Benjamin M. Greenberg, Xin Chen, Berge A. Minassian, Ronald Cohn, Carsten G. Bonnemann, Steven J. Gray",Gene therapy,10.1038/s41591-024-03078-4,Articles%20database/s41591-024-03078-4.pdf,,Nature Medicine,Single-patient intrathecal AAV9-AP4M1 was developed and given to a child with SPG50. At 12 months no serious adverse events were observed; transient neutropenia and C. difficile occurred. Early efficacy signals indicate disease stabilization and motor/cognitive improvements; further follow-up required.,,Yes,,Done,Researchers developed an individualized scAAV9-AP4M1 gene replacement therapy for a single child with SPG50 and administered 1×10^15 vg intrathecally. Through 12 months the treatment was well tolerated with no serious adverse events; transient neutropenia and C. difficile infection occurred. Preliminary measures suggest disease stabilization and some motor/cognitive gains; longer follow-up is needed.,Clinical trial (Phase 1 single-patient),2024
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A,,"Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F. Pierce, Wing Y. Wong, K. John Pasi",Gene therapy (Hematology),10.1056/NEJMoa1708483,Articles%20database/NEJMoa1708483.pdf,,The New England Journal of Medicine,"Single IV AAV5-hFVIII-SQ in 9 men: high dose achieved sustained normalization of FVIII in 6/7 at 1 year, marked reduction in bleeding and FVIII use, mild ALT elevations, no neutralizing FVIII antibodies; small phase 1–2 study.",,Yes,,Done,"Phase 1–2 dose-escalation study of a single IV infusion of AAV5-hFVIII-SQ in nine men with severe hemophilia A. High-dose (6×10^13 vg/kg) produced sustained normal FVIII levels (>50 IU/dL) at 1 year in 6/7 participants, large reductions in bleeding and exogenous FVIII use, mild transient ALT rises, and no FVIII inhibitors.",Clinical trial (Phase 1–2),2017
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A,,"K. John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Michael Laffan, Chris B. Russell, Mingjin Li, Glenn F. Pierce, Wing Y. Wong",Gene therapy,10.1056/NEJMoa1908490,Articles%20database/NEJMoa1908490.pdf,,The New England Journal of Medicine,"Single AAV5-hFVIII-SQ dosing produced sustained FVIII levels for up to 3 years, markedly reduced bleeding and prophylactic FVIII use, resolved target-joint bleeding, and had no inhibitor development or persistent liver toxicity; transient ALT rises managed with glucocorticoids.",,Yes,,Done,"Phase 1–2 study of a single AAV5-hFVIII-SQ infusion in adults with severe hemophilia A showed durable FVIII expression up to 3 years, large reductions in annualized bleeding (≈92–96%) and exogenous FVIII use, resolution of target‑joint bleeding, and no inhibitors, thromboses, deaths, or persistent liver injury.",Clinical trial (Phase 1–2),2020
Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment,,"Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Priyanka Raheja, Tara M. Robinson, Dane Osmond, Chris B. Russell, Christian Vettermann, Suresh K. Agarwal, Mingjin Li, Wing Yen Wong, Michael Laffan","Gene therapy, Hematology",10.1111/hae.14936,Articles%20database/Haemophilia_-_2024_-_Symington_-_Longterm_safety_and_efficacy_outcomes_of_valoctocogene_roxaparvovec_gene_transfer_up_to_6.pdf,,Haemophilia,"Up to 6 years post-treatment, valoctocogene roxaparvovec sustained marked reductions in bleeding and FVIII use, maintained mean FVIII in mild range, had no new safety signals or inhibitors; a parotid acinar cell carcinoma was investigated and not attributed to vector integration.",,Yes,,Done,Phase 1/2 follow-up up to 6 years showed valoctocogene roxaparvovec maintained haemostatic benefit with >90% reductions in annualised treated bleeds and FVIII infusions. Mean FVIII activity remained in mild range (9.8 and 7.6 IU/dL). No new treatment-related safety signals or FVIII inhibitors; one parotid acinar cell carcinoma was not linked to vector integration.,Clinical trial (Phase 1/2),2024
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A,,"Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Margareth C. Ozelo, Gili Kenet, Flora Peyvandi, Michael Wang, Bella Madan, Nigel S. Key, Michael Laffan, Amy L. Dunn, Jane Mason, Doris V. Quon, Emily Symington, Andrew D. Leavitt, Johannes Oldenburg, Hervé Chambost, Mark T. Reding, Kala Jayaram, Hua Yu, Reena Mahajan, Konstantia-Maria Chavele, Divya B. Reddy, Joshua Henshaw, Tara M. Robinson, Wing Yen Wong, Steven W. Pipe",Gene therapy (Hematology),10.1056/NEJMoa2211075,Articles%20database/NEJMoa2211075.pdf,,The New England Journal of Medicine,"Single-dose AAV5-mediated valoctocogene roxaparvovec produced durable transgene-derived FVIII, an 84.5% reduction in treated bleeds and 98% less exogenous FVIII use at 2 years; model half-life ~123 weeks. No new safety signals; transient ALT elevations; anti-AAV5 antibodies developed.",,Yes,,Done,"In a multicenter open-label phase 3 trial (134 men), a single IV dose of valoctocogene roxaparvovec (6×10^13 vg/kg) reduced annualized treated bleeding rate by 84.5% at 104 weeks and cut factor VIII use by 98.2%. Transgene-derived FVIII activity was durable (model half-life ~123 weeks), safety profile manageable (transient ALT rises); anti-AAV5 antibodies developed.",Clinical trial (Phase 3),2023
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B,,"Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Giancarlo Castaman, Wolfgang Miesbach, Susan Lattimore, Kathelijne Peerlinck, Paul Van der Valk, Michiel Coppens, Peter Kampmann, Karina Meijer, Niamh O’Connell, K. John Pasi, Daniel P. Hart, Rashid Kazmi, Jan Astermark, Cedric R.J.R. Hermans, Robert Klamroth, Richard Lemons, Nathan Visweshwar, Annette von Drygalski, Guy Young, Shelley E. Crary, Miguel Escobar, Esteban Gomez, Rebecca Kruse-Jarres, Doris V. Quon, Emily Symington, Michael Wang, Allison P. Wheeler, Robert Gut, Ying P. Liu, Ricardo E. Dolmetsch, David L. Cooper, Yanyan Li, Brahm Goldstein, Paul E. Monahan",Hematology (Gene therapy),10.1056/NEJMoa2211644,Articles%20database/NEJMoa2211644.pdf,,The New England Journal of Medicine,"Single infusion of AAV5-Padua factor IX (etranacogene dezaparvovec) in 54 men with hemophilia B produced sustained increases in factor IX activity, a 64% reduction in annualized bleeding rate, large reductions in factor IX use, and a favorable safety profile; effective despite preexisting AAV5 antibodies up to titer ≈678.",,Yes,,Done,"In a multicenter phase 3 open-label trial of 54 men with moderate-to-severe hemophilia B, a single infusion of AAV5-Padua factor IX gene therapy (etranacogene dezaparvovec) markedly increased factor IX activity (mean ~39% at 6 months, sustained to 18 months), reduced annualized bleeding rate (4.19 to 1.51; rate ratio 0.36), decreased factor IX use, and showed a favorable safety profile. Efficacy observed despite preexisting AAV5 neutralizing antibodies up to titer ~678.",Clinical trial (Phase 3),2023
Efficient kidney gene transfer and proximal tubule transduction using self-complementary AAV.cc47 vectors,,"Jennifer L. Peek, Alan Rosales, Julie Qi, Lena Feleke, Anna Menshikh, Richard C. Welch, Lauren E. Woodard, Aravind Asokan, Matthew H. Wilson",Gene therapy,10.1016/j.omtm.2025.101606,Articles%20database/Efficient_kidney_gene_transfer_and_proximal_tubule_transduction_using_self-complementary_AAV.cc47_vectors_2.pdf,,Molecular Therapy: Methods & Clinical Development,"AAV.cc47 outperforms AAV9 for kidney gene transfer, selectively transducing proximal convoluted tubule (Sglt2+) with >80% PT transduction at low systemic doses; validated in human kidney organoids; QuPath-based cell classification and dual-AAV split transgenes enable quantitative assessment and expanded payload delivery.",,Yes,,Done,"Preclinical study showing AAV.cc47 (self-complementary) achieves robust kidney transduction in mice and human kidney organoids, preferentially targeting proximal tubule epithelium (especially Sglt2+ convoluted segments). At systemic doses ≥1×10^11 vg, >80% of PT epithelium was transduced. Authors developed an automated QuPath quantification pipeline and demonstrated dual-AAV split-transgene delivery for larger payloads.",Preclinical,2025
Overlap Between Ophthalmology And Psychiatry – A Narrative Review Focused on Congenital and Inherited Conditions,,"Chelsea Kiely, Konstantinos AA Douglas, Vivian Paraskevi Douglas, John B. Miller, Paulo Lizano",Psychiatry/Ophthalmology,10.1016/j.psychres.2023.115629,Articles%20database/nihms-1947887.pdf,,Psychiatry Research,"Many congenital and inherited diseases present with both ocular and psychiatric features. Advances combining OCT, brain imaging and genetics reveal eye–brain connections. Early recognition and multidisciplinary management improve outcomes; further work needed to validate retinal biomarkers.",,Yes,,Done,"Narrative review of congenital and inherited disorders that present both ophthalmic and psychiatric features. Summarizes clinical phenotypes, molecular mechanisms, diagnostic testing, and management. Highlights combined retinal and brain imaging with genetic testing revealing eye–brain connections and advocates early recognition, multidisciplinary care, and further research into noninvasive retinal biomarkers.",Review (Narrative Review),2024
Allosteric activators of Ocrl1: a novel therapeutic strategy against Lowe syndrome,,"Ruben Claudio Aguilar, Swetha Ramadesikan, Kayalvizhi Madhivanan, Lisette Skiba, Jennifer Lee",Therapeutics,10.1096/fasebj.2020.34.s1.03527,Articles%20database/Allosteric_activators_of_Ocrl1__a_novel_therapeutic_strategy_against_Lowe_syndrome_-_Aguilar_-_2020_-_The_FASEB_Journal_-_Wiley_Online_Library.pdf,,The FASEB Journal,"4-PBA restores Ocrl1 catalytic activity and corrects localization and Golgi defects in conformational mutants; two other FDA-approved drugs ameliorate signaling and phenotypes in patient cells and an animal model, suggesting repurposing potential.",,Yes,,Done,"Preclinical study showing that the FDA-approved chemical chaperone 4-Phenyl Butyric Acid (4-PBA) can restore catalytic activity and correct cellular phenotypes of conformationally-affected Ocrl1 mutants causing Lowe syndrome. Two additional FDA-approved drugs improved signaling and phenotypes in patient cells and an animal model, supporting repurposing and a conformational/misfolding disease mechanism.",Preclinical,2020
,,,,,Articles%20database/ddaa086%201.pdf,,,,,No,,,,,